****

**Community Services and Health Legislation Amendment Act 1989**

**No. 95 of 1989**

**TABLE OF PROVISIONS**

PART 1—PRELIMINARY

Section

1. Short title

2. Commencement

PART 2—AMENDMENTS OF THE AUSTRALIAN INSTITUTE OF HEALTH ACT 1987

3. Principal Act

4. Interpretation

5. Directions by Minister

6. Confidentiality

PART 3—AMENDMENTS OF THE HEALTH INSURANCE ACT 1973

7. Principal Act

8. Interpretation

9. Certification of in-patient as needing acute care

10. Insertion of new sections:

3f Vocationally registered general practitioners

3g. Removal from Register

3h. Minister’s powers to make determinations

11. Repeal of section 4a and substitution of new section:

4a. Variations and alterations of pathology services table

12. Multiple pathology services

13. Manner of making determinations under sections 4ba and 4bb

14. Increased fee in complex cases

15. Appeal from decision on increased fee

TABLE OF PROVISIONS—*continued*

Section

16. Repeal of provisions establishing the Pathology Services Advisory Committee

17. Prohibition of certain medical insurance

18. Repeal of Schedule 1a and substitution of new Schedule

PART 4—AMENDMENTS OF THE NATIONAL HEALTH ACT 1953

19. Principal Act

20. Interpretation

21. Insertion of new sections:

4b. Determinations—professional attention

4c. Certificates in respect of professional attention

4d. Determination—amount of benefit

22. Repeal of section 5 and substitution of new section:

5. Certain determinations to be disallowable instruments

23. Interim decisions on applications under subsection 40ad (1b)

24. Application by proprietor of home for patient classification

25. Review by Secretary of classification

26. Insertion of new sections:

40afg. Determination by Secretary where classifications found to be inaccurate

40afh. Review of determination

40afj. Effect of determination on applications for patient classification

40afk. Proprietor to be given notice of classification of classified patient admitted to nursing home

27. Insertion of new section:

67a. Injunctions for contravention of section 67

28. Application by organisation for registration as health benefits organisation or to carry on health insurance business

29. Giving of information by applicant organisations

30. Application to be referred to Committee

31. Report of the Committee

32. Matters to be taken into account by Committee and by Ministers

33. Registration and permission to carry on business as registered health benefits organisation

34. Registered organisation not to carry on other business etc.

35. Minimum reserves

36. Exemption from maximum reserve conditions

37. Reinsurance Account in health benefits fund

38. Health Benefits Reinsurance Trust Fund

39. Repeal

40. Conduct of health benefits funds

41. Repeal of sections 76, 76a and 77

42. Changes of rules etc. by registered organisations

43. Cancellation of registration of organisation

44. Offences

45. Insertion of new Part:

PART VIaa—PRIVATE HEALTH INSURANCE ADMINISTRATION COUNCIL

*Division 1—Preliminary*

82a. Interpretation

*Division 2*—*Establishment and Constitution of Council*

82b. Establishment

82c. Commissioner

82d. Constitution of Council

82e. Appointment of non-Commissioner members

82f. Guidelines

TABLE OF PROVISIONS—*continued*

Section

*Division 3*—*Functions and powers of Council*

82g. Functions

82h. Powers

82j. Directions by Minister

82k. Examination of records, books and accounts of registered organisations

82l. Registered organisation to give information to the Council annually

82m. Registered organisation to comply with Council’s reporting requirements

*Division 4—Administration*

82n. Meetings of Council

82p. Delegation by Council

82pa. Annual report by Council

*Division 5*—*Offices of Members*

82pb. Validity of appointments

82pc. Acting Commissioner

82pd. Deputies of members

*Division 6***—***Conditions of Members*

82pe. Remuneration and allowances of members

82pf. Resignation

82pg. Termination of appointment

*Division 7*—*Director and Staff*

82ph. Director

82pj. Duties of Director

82pk. Conflict of interests

82pl. Staff and consultants

82pm. Remuneration and allowances of Director

46. Investigation of organisation by inspector

47. Application for judicial management or winding up of a fund

48. Merger of funds

49. Application for review by Tribunal

50. Officers to observe secrecy

51. Insertion of new section:

138a. Telephone access to offices

52. Regulations

53. Schedule

54. Saving

PART 5—AMENDMENTS OF THE NURSING HOMES ASSISTANCE ACT 1974

55. Principal Act

56. Interpretation

57. Approval in principle of nursing home etc.

58. Approval of nursing home

59. Application of National Health Act

60. Approval of additional services

61. Common form of nursing home agreement

62. Certain notices to be subject to disallowance

PART 6—AMENDMENT OF THE REMUNERATION TRIBUNAL ACT 1973

63. Principal Act

64. Inquiries and determinations by Tribunal

TABLE OF PROVISIONS—*continued*

Section

PART 7—AMENDMENTS OF THE STATES GRANTS (NURSE EDUCATION TRANSFER ASSISTANCE) ACT 1985

65. Principal Act

66. Interpretation

67. Special nurse education transfer grants

68. Addition of new section:

10. Regulations

SCHEDULE

NEW SCHEDULE 1A TO THE HEALTH INSURANCE ACT 1973

****

**Community Services and Health Legislation Amendment Act 1989**

**No. 95 of 1989**

**An Act to amend laws relating to community services and health, and for related purposes**

[*Assented to 28 June 1989*]

BE IT ENACTED by the Queen, and the Senate and the House of Representatives of the Commonwealth of Australia, as follows:

**PART 1—PRELIMINARY**

**Short title**

**1.** This Act may be cited as the *Community Services and Health Legislation Amendment Act 1989.*

**Commencement**

**2.** **(1)** Subject to subsections (2), (3), (4), (5), (6), (7), (8), (9) and (10), this Act commences on the day on which it receives the Royal Assent.

**(2)** Part 7 shall be taken to have commenced on 1 January 1989.

**(3)** Section 23 shall be taken to have commenced on 15 March 1989.

**(4)** Paragraphs 37 (a) to (k) (inclusive) and (s) commence, or shall be taken to have commenced, on 1 June 1989.

**(5)** Part 5 commences on 1 July 1989.

**(6)** Sections 11, 12, 13, 14, 15, 16 and 18 and the Schedule commence on 1 August 1989.

**(7)** Subject to subsection (8), subsection 20 (2), sections 21, 22, 28, 29, 30, 31, 32, 33, 43 and 44, subsection 53 (2) and section 54 commence on a day or days to be fixed by Proclamation.

**(8)** If a provision referred to in subsection (7) does not commence within the period of 6 months beginning on the day on which this Act receives the Royal Assent, it commences at the end of that period.

**(9)** Subject to subsection (10), section 10 commences on a day to be fixed by Proclamation.

**(10)** The day fixed by Proclamation for the commencement of section 10 shall be a day not earlier than the day immediately after the day on which the Senate, by resolution, having concluded debate on the report of the Senate Select Committee on Health Legislation and Health Insurance on section 10 of this Act, approves proposed new sections 3f, 3g and 3h of the *Health Insurance Act 1973* as contained in section 10 of this Act.

**PART 2—AMENDMENTS OF THE AUSTRALIAN INSTITUTE OF HEALTH ACT 1987**

**Principal Act**

**3.** In this Part, “Principal Act” means the *Australian Institute of Health Act 1987*1.

**Interpretation**

**4.** Section 3 of the Principal Act is amended by inserting the following definition in subsection (1):

“ ‘State Health Minister’ means:

(a) the Minister of the Crown for a State;

(b) the Minister of the Australian Capital Territory; or

(c) the Minister of the Northern Territory;

who is responsible, or principally responsible, for the administration of matters relating to health in the State, the Australian Capital Territory or the Northern Territory, as the case may be;”.

**Directions by Minister**

**5.** Section 7 of the Principal Act is amended by inserting in subsection (1) “and each of the State Health Ministers” after “with the Chairperson”.

**Confidentiality**

**6.** Section 29 is amended:

**(a)** by omitting paragraphs (2) (b) and (c) and substituting the following paragraphs:

“(b) a person from divulging or communicating information, or producing a document, to a person specified in writing by the person (in this subsection called the ‘information provider’) who divulged or communicated the information, or produced the document, directly to the Institute;

(c) a person from divulging or communicating information, or producing a document, to a person specified in writing by the Australian Institute of Health Ethics Committee if to do so is not contrary to the written terms and conditions (if any) upon which the information provider divulged or communicated the information, or produced the document, directly to the Institute; or

(d) the publication of conclusions based on statistics derived from, or of particulars of procedures used in, the work of the Institute, if:

(i) to do so is not contrary to the written terms and conditions (if any) upon which an information provider divulged or communicated information relevant to the publication, or produced a document relevant to the publication, directly to the Institute; and

(ii) the publication does not identify the information subject.”;

**(b)** by omitting from subsection (3) “or (b)” and substituting “, (b) or (c),”;

**(c)** by omitting from paragraph (4) (b) all words from and including “and” and substituting the following words and subparagraphs:

“and also includes:

(i) in the case of an information provider—a body politic; or

(ii) in the case of an information subject—a deceased person.”.

**PART 3—AMENDMENTS OF THE HEALTH INSURANCE ACT 1973**

**Principal Act**

**7.** In this Part, “Principal Act” means the *Health Insurance Act 1973*2*.*

**Interpretation**

**8.** Section 3 of the Principal Act is amended by inserting in subsection (1) the following definition:

“ ‘vocationally registered general practitioner’ means a medical practitioner registered under section 3f;”.

**Certification of in-patient as needing acute care**

**9.** **(1)** Section 3b of the Principal Act is amended:

**(a)** by omitting from paragraph (5) (b) “an application in writing is made to him” and substituting “receiving from the Private Health Insurance Administration Council a copy of an application in writing made to it”;

**(b)** by omitting subsection (8) and substituting the following subsection:

“(8) The Secretary may establish a Committee or Committees to be known as the Acute Care Advisory Committee or the Acute Care Advisory Committees.”.

**(2)** Notwithstanding the amendments made by this section, an Acute Care Advisory Committee reviewing a certificate on the commencement of this section shall continue the review as if the amendment had not been made.

**10.** After section 3e of the Principal Act the following sections are inserted:

**Vocationally registered general practitioners**

“3f. (1) The purpose of this section is to provide for the registration of certain medical practitioners as vocationally registered general practitioners.

*Note*:Some items in the general medical services table apply only to services rendered by medical practitioners who are registered under this section.

“(2) The Commission is to establish and maintain a Vocational Register of General Practitioners.

“(3) The Register may be maintained in any form, including the form of a computer record.

“(4) A medical practitioner may apply to the Commission for registration under this section.

“(5) The application must be made in a manner approved by the Minister.

“(6) If:

(a) the General Manager of the Commission is satisfied that the Royal Australian College of General Practitioners has certified that the applicant’s medical practice is predominantly general practice and

that the applicant has training and experience in general practice that make it appropriate for the applicant to be registered under this section; or

(b) the applicant is, in accordance with the regulations, eligible for registration under this section;

the General Manager shall, within 14 days after receiving the application, enter the applicant’s name in the Register.

“(7) The General Manager of the Commission shall give the applicant written notice of the day on which the applicant’s name is to be entered in the Register.

“(8) The Commission may give the Royal Australian College of General Practitioners information about:

(a) the current state of the Register;

(b) additions to the Register; and

(c) deletions from the Register.

“(9) The General Manager of the Commission or an authorised officer may make available to members of the public, on request, the names of medical practitioners who are registered under this section and the addresses at which they practise.

“(10) In the section:

‘authorised officer’ means a Commission staff member authorised by the General Manager of the Commission as an authorised officer for the purposes of this section;

‘Commission staff member’ means a member of the staff of the Commission referred to in subsection 28 (1) of the *Health Insurance Commission Act 1973.*

**Removal from Register**

“3g. (1) The General Manager of the Commission shall remove a medical practitioner’s name from the Vocational Register of General Practitioners if:

(a) the medical practitioner requests the General Manager to do so;

(b) the Royal Australian College of General Practitioners gives the General Manager written notice that:

(i) the College is no longer satisfied that the medical practitioner’s medical practice is predominantly general practice;

(ii) the College is no longer satisfied that it is appropriate for the medical practitioner to be registered under section 3f; or

(iii) the medical practitioner has failed to meet the College’s minimum requirements for participation in continuing medical education and quality assurance programs; or

(c) removal is required by regulations made for the purposes of this paragraph.

“(2) Where the General Manager decides that a medical practitioner’s name should be removed from the Register, the General Manager shall give the medical practitioner written notice of the decision.

“(3) The decision shall be made in writing and shall specify the day on which the medical practitioner’s name is to be removed from the Register.

“(4) The day specified under subsection (3) shall be not less than 14 days after the day on which the decision is made.

**Minister’s powers to make determinations**

“3h. (1) The Minister may, by notice published in the *Gazette*,determine that a reference in section 3f or 3g to the Royal Australian College of General Practitioners is to be taken to be a reference to the body specified in the determination.

“(2) If a determination is made under subsection (1), section 3f or 3g applies as if the reference to the College were a reference to the body specified in the determination.”.

**11.** Section 4a of the Principal Act is repealed and the following section is substituted:

**Variations and alterations of pathology services table**

“4a. (1) The regulations may provide that this Act shall have effect as if the pathology services table were varied:

(a) by omitting an item or rule of interpretation from the table;

(b) by inserting an item or rule of interpretation in the table; or

(c) by substituting another amount for an amount set out in the table.

“(2) The regulations may prescribe a table of pathology services in accordance with the form of table set out in Schedule 1a.

“(3) On the commencement of a regulation prescribing a table of pathology services:

(a) the table so prescribed has effect as if it were set out in Schedule 1a in the place of the table (in this subsection referred to as ‘the superseded table’) in that Schedule; and

(b) the superseded table or, if another table has effect, by virtue of this section, in the place of the superseded table, that other table ceases to have effect.

“(4) The regulations may amend a table that has effect by virtue of paragraph (3) (a) and, on the commencement of the amendment, the table as so amended has effect in the place of the first-mentioned table.

“(5) In this section, a reference to a table of pathology services shall be read as including a reference to rules for the interpretation of that table.

“(6) Regulations under this section shall, unless sooner repealed, cease to be in force on the day next following the 15th sitting day of the House

of Representatives after the expiration of a period of 12 months commencing on the day on which the regulations are notified in the *Gazette*,and shall be deemed to have been repealed on the first-mentioned day.”.

**Multiple pathology services**

**12.** Section 4b of the Principal Act is amended by omitting from subsection (2) “determination” and substituting “regulation”.

**Manner of making determinations under sections 4ba and 4bb**

**13.** Section 4bc of the Principal Act is amended by omitting from subsection (1) “4a,”.

**Increased fee in complex cases**

**14.** Section 11 of the Principal Act is amended:

**(a)** by omitting from subsections (2) “the professional service referred to in the claim is a service other than a pathology service and”;

**(b)** by omitting subsection (2a);

**(c)** by omitting from subsection (3) “or (2a) (b)”.

**Appeal from decision on increased fee**

**15.** Section 12 of the Principal Act is amended:

**(a)** by omitting from subsections (2), (3), (4) and (6) “relevant committee” (wherever occurring) and substituting “Medicare Benefits Advisory Committee”;

**(b)** by omitting subsection (8).

**Repeal of provisions establishing the Pathology Services Advisory Committee**

**16.** Division 2a of Part V of the Principal Act is repealed.

**Prohibition of certain medical insurance**

**17.** Section 126 of the Principal Act is amended:

**(a)** by omitting from subsection (1) “indemnify the other person in respect of loss arising out” and substituting “make a payment in the event”;

**(b)** by omitting from subsection (2) “indemnify a person in respect of loss arising out” and substituting “make a payment in the event”.

**Repeal of Schedule 1a and substitution of new Schedule**

**18.** Schedule 1a to the Principal Act is repealed and the Schedule set out in the Schedule to this Act is substituted.

**PART 4—AMENDMENTS OF THE NATIONAL HEALTH ACT 1953**

**Principal Act**

**19.** In this Part, “Principal Act” means the *National Health Act 1953*3*.*

**Interpretation**

**20. (1)** Section 4 of the Principal Act is amended by inserting in subsection (1) the following definitions:

“ ‘Council’ means the Private Health Insurance Administration Council established by section 82b;

‘Council’s rules’ means rules made by the Council in the performance of its functions under paragraph 82g (r);”.

**(2)** Section 4 of the Principal Act is amended:

**(a)** by omitting paragraph (a) of the definition of “basic private table” or “basic table” in subsection (1) (in this section called the “relevant definition”) and substituting the following paragraph:

“(a) in respect of hospital treatment provided to patients (other than nursing-home type patients) in a hospital in the State or Territory to which the table relates for the purpose of permitting the provision to them at the hospital of:

(i) type-A professional attention; or

(ii) professional attention that, under subsection 4c (1), is taken to be professional attention to which this paragraph applies;

where the hospital treatment has been provided for a period that includes part of an overnight stay—benefits equal to the amount of the standard hospital fees in relation to that State or Territory;”;

**(b)** by omitting from paragraph (b) of the relevant definition “persons as in-patients” and “that patient is an in-patient” and substituting “nursing-home type patients” and “hospital treatment is provided to that patient” respectively;

**(c)** by omitting from paragraph (b) of the relevant definition “, being nursing-home type patients”;

**(d)** by omitting from paragraph (c) of the relevant definition “persons as in-patients” and “that patient was an in-patient” and substituting “nursing-home type patients” and “hospital treatment is provided to that patient” respectively;

**(e)** by omitting from paragraph (c) of the relevant definition “, being nursing-home type patients”;

**(f)** by omitting from paragraph (d) of the relevant definition “persons as in-patients” and substituting “patients”;

**(g)** by omitting from paragraph (da) of the relevant definition “the person is an in-patient of” and substituting “hospital treatment is provided to the person in”;

**(h)** by omitting paragraphs (db) and (dc) of the relevant definition and substituting the following paragraphs:

“(db) in respect of hospital treatment provided to a patient in a hospital for the purpose of permitting the provision to the patient at the hospital of:

(i) type-A professional attention;

(ii) type-B professional attention; or

(iii) professional attention that is, under subsection 4c (2), to be taken to be professional attention to which this paragraph applies;

where the hospital treatment has been provided for a period that does not include part of an overnight stay—a benefit equal to the amount that, under the determination made by the Minister under paragraph 4d (1) (a), is payable in respect of that hospital treatment;

(dc) in respect of hospital treatment provided to a person in a day hospital facility for the purpose of permitting the provision to the person at the day hospital facility of professional attention other than type-C professional attention—a benefit equal to the amount that, under the determination made by the Minister under paragraph 4d (1) (b), is payable in respect of that hospital treatment;”;

**(j)** by omitting from paragraph (dd) of the relevant definition “person who is an in-patient” and substituting “patient while hospital treatment is provided to the patient”;

**(k)** by inserting in subsection (1) the following definitions:

“ ‘patient’, in relation to a hospital, does not include:

(a) a member of the staff of the hospital who is receiving treatment in his or her own quarters; or

(b) except as provided by subsection 3 (2) of the *Health Insurance Act 1973*,a newly-born child whose mother also occupies a bed in the hospital;

‘type-A professional attention’ means professional attention, other than professional attention to which a determination under paragraph 4b (a) relates, the provision of which to a patient normally requires that the patient be given hospital treatment in a hospital;

‘type-B professional attention’ means professional attention to which a determination under paragraph 4b (a) relates;

‘type-C professional attention’ means professional attention to which a determination under paragraph 4b (b) relates;”.

**21.** After section 4a of the Principal Act the following sections are inserted:

**Determinations—professional attention**

“4b. The Minister may make the following determinations in writing:

(a) a determination that the provision of professional attention of a kind specified in the determination normally requires hospital treatment in a hospital but does not require such hospital treatment for a period that includes part of an overnight stay;

(b) a determination that the provision of professional attention of a kind specified in the determination does not normally require hospital treatment.

**Certificates in respect of professional attention**

“4c. (1) Where:

(a) hospital treatment is provided, for a period that includes part of an overnight stay, to a patient in a hospital for the purpose of permitting the provision to the patient at the hospital of professional attention other than type-A professional attention; and

(b) the practitioner providing the professional attention certifies in writing that:

(i) because of the medical condition of the patient specified in the certificate; or

(ii) because of the special circumstances specified in the certificate;

it would be contrary to accepted medical practice to provide the professional attention to the patient unless the patient were given hospital treatment in the hospital for a period that includes part of an overnight stay;

the professional attention shall be taken to be professional attention to which paragraph (a) of the definition of ‘basic private table’ or ‘basic table’ in subsection 4 (1) (in this section called the ‘relevant definition’) applies.

“(2) Where:

(a) hospital treatment is provided, for a period that does not include part of an overnight stay, to a patient in a hospital for the purpose of permitting the provision to the patient at the hospital of professional attention other than type-A professional attention or type-B professional attention; and

(b) the practitioner providing the professional attention certifies in writing that:

(i) because of the medical condition of the patient specified in the certificate; or

(ii) because of the special circumstances specified in the certificate;

it would be contrary to accepted medical practice to provide the professional attention to the patient unless the patient were given hospital treatment in the hospital for a period that does not include part of an overnight stay;

the professional attention shall be taken to be professional attention to which paragraph (db) of the relevant definition applies.

**Determination—amount of benefit**

“4d. (1) The Minister may, in relation to a State or Territory:

(a) determine, for the purposes of paragraph (db) of the definition of ‘basic private table’ or ‘basic table’ in subsection 4 (1) (in this section called the ‘relevant definition’), the amount payable in respect of hospital treatment provided in hospitals in the State or Territory; and

(b) determine, for the purposes of paragraph (dc) of the relevant definition, the amount payable in respect of hospital treatment provided in day hospital facilities in the State or Territory.

“(2) In making a determination under subsection (1), the Minister may determine:

(a) different amounts in respect of hospital treatment relating to the provision of different classes of professional attention; and

(b) in the case of a determination for the purposes of paragraph (db) of the relevant definition—different amounts in respect of hospital treatment provided in different classes of hospital.”.

**22.** Section 5 of the Principal Act is repealed and the following section is substituted:

**Certain determinations to be disallowable instruments**

“5. (1) In this section:

‘determination’ means:

(a) a determination for the purposes of paragraph (dd) of the definition of ‘basic private table’ or ‘basic table’ in subsection 4 (1);

(b) a determination under section 4b; or

(c) a determination under subsection 4d (1).

“(2) A determination is a disallowable instrument for the purposes of section 46a of the *Acts Interpretation Act 1901*.”.

**Interim decisions on applications under subsection 40ad (1b)**

**23.** Section 40ada of the Principal Act is amended by omitting from subsection (6) “(2)” and substituting “(1)”.

**Application by proprietor of home for patient classification**

**24.** Section 40afd of the Principal Act is amended:

**(a)** by omitting from subsection (1) “When” and substituting “Subject to section 40afj, when”;

**(b)** by omitting from subsection (2) “The” and substituting “Subject to section 40afj, the”.

**Review by Secretary of classification**

**25.** Section 40afe of the Principal Act is amended by omitting from subsection (5) all words to and including “written” and substituting the following:

“The Secretary shall, as soon as practicable, give in writing:

(a) to the proprietor of the nursing home; and

(b) if another person or body applied for the classification of the nursing home patient under section 40afd—to that other person or body;”.

**26.** After section 40aff of the Principal Act the following sections are inserted:

**Determination by Secretary where classifications found to be inaccurate**

“40afg. (1) In subsection (2):

‘review’ means:

(a) a review under section 40afe; or

(b) where a review under that section has been confirmed by the Minister under section 40aff, the review as so confirmed by the Minister.

“(2) Where reviews of classifications of patients in a nursing home have in a substantial number of cases resulted in:

(a) those classifications being revoked on the ground that they were based on inaccurate information given by the proprietor of the nursing home; and

(b) lower classifications being substituted for them;

the Secretary may:

(c) determine in writing that section 40afd does not apply in relation to the proprietor; and

(d) nominate in the determination the person or body who is to make applications for the purposes of that section in the place of the proprietor.

“(3) Unless it is set aside by the Minister under subsection 40afh (2), a determination remains in force for the period specified in the determination.

“(4) The Secretary shall, as soon as practicable, give in writing to the proprietor of the nursing home notice of:

(a) the determination;

(b) the reasons for the determination; and

(c) the rights of the proprietor under section 40afh.

**Review of determination**

“40afh. (1) A proprietor of a nursing home dissatisfied with a determination under subsection 40afg (2) may, within 28 days after the day on which notice of the determination was given to the proprietor, request in writing the Minister to review the determination.

“(2) The Minister shall review the determination and may:

(a) confirm it;

(b) set it aside; or

(c) set it aside and substitute any determination that the Minister thinks appropriate.

“(3) A determination by the Minister under paragraph (2) (c) remains in force for the period specified in the determination.

“(4) The Minister shall, as soon as practicable, give in writing to the proprietor of the nursing home:

(a) notice of his or her decision under subsection (2); and

(b) if the Minister has confirmed the determination of the Secretary or substituted another determination for it—the reasons for the decision.

**Effect of determination on applications for patient classification**

“40afj. Where there is in force a determination under subsection 40afg (2) or 40afh (2) in relation to the proprietor of a nursing home, the following provisions apply:

(a) the proprietor may not apply to the Secretary under section 40afd for the classification of patients in the nursing home;

(b) any application under that section in respect of a patient in the nursing home shall be made by the person or body nominated for that purpose in the determination;

(c) the Secretary shall give to the proprietor notice of any classification in respect of a nursing home patient granted under an application made in accordance with paragraph (b);

(d) where an application under subsection 40afd (2) for the classification of a nursing home patient is made in accordance with paragraph (b):

(i) subsections 40afd (7) to (10) (inclusive) do not apply in relation to the application; and

(ii) the classification granted on the application takes effect, or is to be regarded as having taken effect, at the expiration of the previous classification of the patient.

**Proprietor to be given notice of classification of classified patient admitted to nursing home**

“40afk. Where a person in respect of whom a classification under section 40afa is in force is admitted to an approved nursing home, the Secretary shall, on request, give to the proprietor of the nursing home

written notice of the classification and of the day on which the classification expires.”.

**27.** After section 67 of the Principal Act the following section is inserted:

**Injunctions for contravention of section 67**

“67a. (1) Where, on the application of the Minister, the Council or any other person, the Federal Court of Australia is satisfied that a person has engaged, or is proposing to engage, in conduct that constitutes or would constitute a contravention of subsection 67 (1), the Court may grant an injunction in such terms as the Court determines to be appropriate.

“(2) Where in the opinion of the Court it is desirable to do so, the Court may grant an interim injunction pending determination of an application under subsection (1).

“(3) The Court may rescind or vary an injunction granted under subsection (1) or (2).

“(4) The power of the Court to grant an injunction restraining a person from engaging in conduct may be exercised:

(a) whether or not it appears to the Court that the person intends to engage again, or to continue to engage, in conduct of that kind; and

(b) whether or not the person has previously engaged in conduct of that kind.

“(5) The power of the Court to grant an injunction requiring a person to do an act or thing may be exercised:

(a) whether or not it appears to the Court that the person intends to refuse or fail again, or to continue to refuse or fail, to do that act or thing; and

(b) whether or not the person has previously refused or failed to do that act or thing.”.

**Application by organisation for registration as health benefits organisation or to carry on health insurance business**

**28.** **(1)** Section 68 of the Principal Act is amended:

**(a)** by omitting subsection (1) and substituting the following subsections:

“(1) In this section:

‘State’, except in subsections (2), (2a) and (3), includes the Northern Territory.

“(1a) An organisation may apply for registration as a registered health benefits organisation.

“(1b) An application shall specify the State or States in which the organisation proposes to carry on business as a registered health benefits organisation.

“(1c) It is a condition of the registration of a registered health benefits organisation that it only carries on business as a registered health benefits organisation in the State or States:

(a) specified in its application for registration;

(b) specified in a successful application by it under subsection (1d); or

(c) in which it has a fund transferred to it under paragraph 82zp (1) (b).

“(1d) A registered health benefits organisation may apply to carry on business as a registered health benefits organisation in a specified State, or specified States, not specified in its application for registration.”;

**(b)** by omitting from subsection (2) “be registered as a registered health benefits organisation in respect of a State” and substituting “carry on business as a registered health benefits organisation in a State”;

**(c)** by omitting from subparagraph (2) (c) (v) “Administrators” and substituting “Council”;

**(d)** by omitting from paragraph (2a) (c) “in respect of” and substituting “in an application specifying, or applies to carry on business as a registered health benefits organisation in,”;

**(e)** by omitting from subsection (3) “be registered as a registered health benefits organisation in respect of and substituting “carry on business as a registered health benefits organisation in”;

**(f)** by omitting subparagraph (3) (a) (i) and substituting the following subparagraph:

“(i) the Northern Territory is to be treated as part of another State in which the organisation, carries on, or proposes to carry on, business as a registered health benefits organisation;”;

**(g)** by omitting from subsection (4) “be registered as a registered health benefits organisation in respect of any State or in respect of the Northern Territory” and substituting “carry on business as a registered health benefits organisation in any State”;

**(h)** by omitting from subparagraph (4) (c) (iv) “Administrators” and substituting “Council”.

**(2)** Where, immediately before the commencement of this section, an organisation was a registered health benefits organisation:

(a) the organisation shall be taken to be registered under section 68 of the Principal Act as amended by this section; and

(b) for the purposes of subsection 68 (1c) of that section, every State and Territory in respect of which the organisation was registered as a registered health benefits organisation immediately before that

commencement shall be taken to have been specified in the application for registration under that section.

**Giving of information by applicant organisations**

**29.** Section 69 of the Principal Act is amended by inserting “, or for permission to carry on business as a registered health benefits organisation” after “registration” (wherever occurring).

**Application to be referred to Committee**

**30.** Section 71 of the Principal Act is amended by inserting “or for permission to carry on business as a registered health benefits organisation” after “registration”.

**Report of the Committee**

**31.** Section 72 of the Principal Act is amended by inserting “, or permission to carry on business as a registered health benefits organisation, as the case requires,” after “organisation”.

**Matters to be taken into account by Committee and by Ministers**

**32.** Section 72a of the Principal Act is amended:

**(a)** by omitting “in respect of and substituting “or for permission to carry on business as a registered health benefits organisation in”;

**(b)** by inserting “or to carry on that business in the State or Territory, as the case may be” after “registered”;

**(c)** by inserting in paragraph (a) “or funds” after “fund”;

**(d)** by inserting in paragraphs (b) and (c) “or those funds” after “fund” (wherever occurring);

**(e)** by inserting in paragraph (d) “in respect of that fund or each of those funds—” before “the ratio”.

**Registration and permission to carry on business as registered health benefits organisation**

**33.** Section 73 of the Principal Act is amended:

**(a)** by inserting in subsection (2aa) “for registration” after “application” (first occurring);

**(b)** by omitting from subsection (2a) “for registration by an organisation” and substituting “by an organisation for registration or to carry on business as a registered health benefits organisation”;

**(c)** by inserting in subsection (2a) “or a relevant fund” after “fund”;

**(d)** by adding at the end the following subsections:

“(9) Where the Minister grants an application by a registered organisation to carry on business as a registered health benefits organisation in a State or the Northern Territory, the Minister shall, within one month after the Minister has granted the application publish in the *Gazette* a notification to that effect setting out:

(a) the name of the organisation; and

(b) the name of the State or Territory.

“(10) Where the Minister refuses an application by a registered organisation to carry on business as a registered health benefits organisation in a State or the Northern Territory, the Minister shall, within one month after so refusing the application publish in the *Gazette* a notification of the refusal.”.

**Registered organisation not to carry on other business etc.**

**34.** Section 73baa of the Principal Act is repealed.

**Minimum reserves**

**35.** Section 73bab of the Principal Act is amended:

**(a)** by omitting subsection (1) and substituting the following subsections:

“(1) It is a condition of registration of a registered organisation that, where it conducts only one health benefits fund, the value of the assets of that fund shall at all times exceed the sum of:

(a) whichever is the higher of:

(i) the prescribed minimum amount; or

(ii) the amount (if any) by which the sum of the amounts debited to that fund during the last preceding prescribed period of the organisation exceeds the amount of income received during that period from assets of that fund consisting of investments;

(b) the liabilities that are required to be met out of that fund;

(c) the amount of any subsisting guarantee, not falling within paragraph (b), given by the organisation in relation to a prescribed company;

(d) the sum of the amounts of payments by way of calls in respect of shares in a prescribed company, not falling within paragraph (b), that the organisation is, or could become, liable to pay; and

(e) any other amount that the Minister, after taking into account the advice of the Council, considers should be a liability for the purposes of this subsection.

“(la) It is a condition of registration of a registered health benefits organisation that, where it conducts 2 or more health benefits funds, the value of the assets of each of those funds shall at all times exceed the sum of:

(a) the amount (if any) by which the sum of the amounts debited to that fund during the last preceding prescribed period of the organisation exceeds the amount of income received during that period from assets of that fund consisting of investments;

(b) the liabilities that are required to be met out of that fund;

(c) so much as the Minister, by instrument in writing, determines of the amount of any subsisting guarantee, not falling within paragraph (b), given by the organisation in relation to a prescribed company;

(d) the amount equal to so much as the Minister, by instrument in writing, determines of the sum of the amounts of payments by way of calls in respect of shares in a prescribed company, not falling within paragraph (b), that the organisation is, or could become, liable to pay; and

(e) any other amount that the Minister, after taking into account the advice of the Council, considers should be a liability for the purposes of this subsection.

“(1b) It is a condition of registration of a registered health benefits organisation that, where it conducts 2 or more health benefits funds, the value of the sum of the assets of all those funds shall at all times exceed the sum of:

(a) whichever is the higher of:

(i) the prescribed minimum amount; or

(ii) the amount (if any) by which the sum of the amounts debited to those funds during the last preceding prescribed period of the organisation exceeds the amount of income received during that period from assets of those funds consisting of investments;

(b) the liabilities that are required to be met out of those funds;

(c) the amount of any subsisting guarantee, not falling within paragraph (b), given by the organisation in relation to a prescribed company;

(d) the sum of the amounts of payments by way of calls in respect of shares in a prescribed company, not falling within paragraph (6), that the organisation is, or could become, liable to pay; and

(e) any other amount that the Minister, after taking into account the advice of the Council, considers should be a liability for the purposes of this subsection.”;

**(b)** by omitting from paragraph (2) (b) “or” (last occurring);

**(c)** by adding at the end of subsection (2) the following word and paragraph:

“; or (d) any property that the Minister, after taking into account the advice of the Council, considers should not be an asset for the purposes of this section.”;

**(d)** by inserting in subsection (3) the following definitions:

“ ‘prescribed minimum amount’ means $1,000,000 or, if a higher amount is prescribed, that higher amount;

‘property’ includes an interest, power, right or privilege;”.

**Exemption from maximum reserve conditions**

**36.** **(1)** Section 73bac of the Principal Act is amended by omitting subsection (1) and substituting the following subsections:

“(1) Upon application in writing made to the Minister by a registered organisation, the Minister, after consulting the Council, may, by notice in writing served on the public officer of the organisation, exempt the organisation from compliance with the conditions referred to in section 73bab.

“(1b) An application by an organisation under subsection (1) shall be accompanied by such evidence, valuations or actuarial certification of the assets and liabilities of the organisation as the Minister considers appropriate.”.

**(2)** Where immediately before the amendment of section 73bab of the Principal Act made by this Act, an exemption of an organisation from compliance with the condition referred to in that section was in force, that exemption shall be taken to be an exemption under subsection 73bac (1) of the Principal Act as amended by subsection (1).

**Reinsurance Account in health benefits fund**

**37.** Section 73bb of the Principal Act is amended:

**(a)** by omitting from subsection (2) “this section” and substituting “subsections (3), (4) and (8)”;

**(b)** by inserting in subsection (2) “or a supplementary hospital table” after “Schedule)”;

**(c)** by inserting in subsection (2) “for a person who has not, or persons who have not, reached the prescribed age” after “matter” (first occurring);

**(d)** by inserting in paragraph (2) (a) “such” before “person”;

**(e)** by inserting in paragraph (2) (b) “such” before “persons” (first occurring);

**(f)** by omitting from subsection (3) “this section” and substituting “subsection (4)”;

**(g)** by omitting from subsection (4) “section” (first occurring) and substituting “subsection”;

**(h)** by inserting in subsection (4) “or a supplementary hospital table” after “Schedule)”;

**(j)** by omitting from subsection (4) “section” (last occurring) and substituting “subsection”;

**(k)** by inserting after subsection (4) the following subsection:

“(5) A registered organisation may debit to the Reinsurance Account maintained by it in a health benefits fund the amounts of any payments of any benefits made out of that fund in accordance

with a basic table (whether or not modified by an election of the kind referred to in the condition set out in paragraph (ba) of the Schedule) or a supplementary hospital table to a contributor in respect of the provision of treatment, a service or another matter for a person who has reached the prescribed age.”;

**(m)** by omitting subsection (5a);

**(n)** by omitting from paragraph (7) (a) “Minister” and substituting “Council”;

**(p)** by omitting paragraph 7 (c) and substituting the following paragraph:

“(c) shall give to the Council, at such times as the Council determines, such information drawn from the records referred to in paragraph (a) as the Council requires.”;

**(q)** by omitting subsection (9) and substituting the following subsection:

“(9) This section only applies to classes of benefits declared by the Minister, by notice published in the *Gazette*,to be classes of benefits for the purposes of reinsurance.”;

**(r)** by omitting from subsection (11) the definition of “nursing home fund benefit”;

**(s)** by inserting in subsection (11) the following definition:

“ ‘prescribed age’ means 65 years or, if another age is prescribed, that other age;”.

**Health Benefits Reinsurance Trust Fund**

**38.** Section 73bc of the Principal Act is amended:

**(a)** by omitting from subsection (1) “and the Commonwealth”;

**(b)** by inserting in that subsection “, and for the Commonwealth to make a payment towards,” before “meeting”;

**(c)** by omitting subsection (4);

**(d)** by omitting paragraph (5) (a) and substituting the following paragraph:

“(a) such amount as is appropriated by the Parliament in the financial year ending on 30 June 1989 for payment into the Fund;”;

**(e)** by omitting subsections (5b), (5c) and (5d) and substituting the following subsections:

“(5b) The Minister shall determine in writing principles relating to the operation of the Fund.

“(5c) The principles shall include principles for determining the method of, and the matters to be taken into account in, calculating the amounts to be paid into the Fund by registered health benefits organisations.

“(5d) Where the Minister determines or varies the principles, he or she shall as soon as practicable:

(a) notify the Council of the principles or variation, as the case may be; and

(b) cause a copy of the principles or particulars of the variation, as the case may be, to be published in the *Gazette.*

“(5e) The Council shall exercise its functions and powers in relation to the Fund in accordance with the principles.”;

**(f)** by omitting from subsection (6) “Administrators determine” and substituting “Council determines”;

**(g)** by omitting from subsection (8) “Administrators determine” and substituting “Council determines”;

**(h)** by omitting from subsection (8) “they” and substituting “it”;

**(j)** by omitting from subsection (9) “Administrators” and substituting “Council”;

**(k)** by omitting from subsection (10) “Administrators make” and substituting “Council makes”;

**(m)** by omitting from subsection (10) “they” and substituting “it”;

**(n)** by omitting from subsection (11) “Administrators” and substituting “Council”;

**(p)** by omitting from subsection (12) “Administrators” (first occurring) and substituting “Council”;

**(q)** by omitting from subsection (12) “Administrators otherwise direct” and substituting “Council otherwise directs”;

**(r)** by omitting from subsection (13) the definition of “Administrator”.

**Repeal**

**39.** Section 73bd of the Principal Act is repealed.

**Conduct of health benefits funds**

**40.** Section 74b of the Principal Act is amended:

**(a)** by omitting from paragraph (c) “and” (last occurring);

**(b)** by inserting after paragraph (c) the following paragraph:

“(ca) the Council’s rules; and”.

**Repeal of sections 76, 76a and 77**

**41.** **(1)** Section 76 of the Principal Act is repealed.

**(2)** Section 76a of the Principal Act is repealed.

**(3)** Section 77 of the Principal Act is repealed.

**Changes of rules etc. by registered organisations**

**42.** Section 78 of the Principal Act is amended:

**(a)** by inserting in subsection (1) “in a form approved by the Minister” after “writing”;

**(b)** by omitting subsections (1a) to (11) (inclusive) and substituting the following subsections:

“(2) The notification shall:

(a) identify the change; and

(b) show that the change is consistent with this Act and the conditions of registration of the organisation.

“(3) Where subsection (1) or (2) is not complied with in relation to a change, that change shall not be taken to have come into operation.

“(4) Where the Minister is of the opinion that a change:

(a) would or might result in a breach of this Act or of a condition of registration of an organisation;

(b) imposes an unreasonable or inequitable condition affecting the rights of any contributors; or

(c) might, having regard to the advice of the Council, adversely affect the financial stability of a health benefits fund;

the Minister may, by declaration in writing, declare that the change shall not be taken to have come into operation.

“(5) The Secretary shall tell the Council of any declaration made by the Minister under paragraph (4) (c).

“(6) Where the Minister makes a declaration under subsection (4) in relation to a notification by an organisation, the Secretary shall tell the organisation of the declaration.”.

**Cancellation of registration of organisation**

**43.** Section 79 of the Principal Act is amended:

**(a)** by omitting subsection (3) and substituting the following subsection:

“(3) The Minister shall cancel the registration of a registered organisation if all health benefits funds conducted by the organisation have been wound up in accordance with Part VIa.”;

**(b)** by omitting subsection (5).

**Offences**

**44.** Section 82 of the Principal Act is amended by inserting in paragraph (1) (a) “or for permission to carry on business as a registered health benefits organisation” after “organisation”.

**45.** After Part VI of the Principal Act the following Part is inserted:

**“PART VIaa—PRIVATE HEALTH INSURANCE ADMINISTRATION COUNCIL**

**“*Division 1*—*Preliminary***

**Interpretation**

“82a. In this Part, unless the contrary intention appears:

‘Commissioner’ means the Commissioner of Private Health Insurance Administration referred to in section 82c;

‘deputy’ means a deputy of a member appointed under section 82pd;

‘Director’ means the Director of the Council referred to in section 82ph;

‘guidelines’ means the guidelines referred to in section 82f;

‘member’ means a member of the Council and includes the Commissioner.

**“*Division 2***—***Establishment and Constitution of Council***

**Establishment**

“82b. (1) There is established a Private Health Insurance Administration Council.

“(2) The Council:

(a) is a body corporate with perpetual succession;

(b) shall have a common seal;

(c) may acquire, hold and dispose of real and personal property; and

(d) may sue and be sued in its corporate name.

“(3) The common seal of the Council shall be kept in such custody as the Council directs and shall not be used except as authorised by the Council.

“(4) All courts, judges and persons acting judicially shall take judicial notice of the imprint of the common seal of the Council appearing on a document and shall presume that it was duly affixed.

**Commissioner**

“82c. (1) There shall be a Commissioner of Private Health Insurance Administration.

“(2) The Commissioner may perform the functions and exercise the powers of the Council and, where he or she performs such a function or exercises such a power, that function or power shall be taken to have been performed or exercised by the Council.

“(3) The Commissioner shall, in the performance of a function or the exercise of a power of the Council, have regard, as far as is practicable, to the advice of the other members.

“(4) The Commissioner shall be appointed by the Minister in accordance with the guidelines.

“(5) The Commissioner shall be appointed on a full-time basis or on a part-time basis.

**Constitution of Council**

“82d. (1) The Council consists of:

(a) the Commissioner;

(b) 3 members representing registered organisations; and

(c) one other member.

“(2) The performance of the functions, or the exercise of the powers, of the Council is not affected by a vacancy or vacancies in the membership of the Council.

**Appointment of non-Commissioner members**

“82e. (1) In this section:

‘member’ does not include the Commissioner.

“(2) The members shall be appointed by the Minister in accordance with the guidelines.

“(3) A member holds office on a part-time basis.

**Guidelines**

“82f. (1) The Minister may, by written instrument, make guidelines, not inconsistent with this Part, relating to:

(a) the appointment of the Commissioner, other members and deputies;

(b) the terms and conditions of their offices; and

(c) their periods of appointment.

“(2) Before making, varying or revoking guidelines, the Minister shall consult with such registered organisations or associations of registered organisations as he or she considers appropriate.

“(3) An instrument referred to in subsection (1) is a disallowable instrument for the purposes of section 46a of the *Acts Interpretation Act 1901.*

**“*Division 3*—*Functions and powers of Council***

**Functions**

“82g. The functions of the Council are:

(a) to administer the Health Benefits Reinsurance Trust Fund;

(b) to obtain from each registered organisation regular reports about the financial affairs of the organisation, including reports supported by actuarial certification;

(c) to establish uniform standards of reporting by registered organisations to the Council;

(d) to examine, from time to time, the financial affairs of registered organisations, by means of the inspection and analysis of the records, books and accounts of the organisations and any other relevant information;

(e) to review, by carrying out independent actuarial assessment, the value of the assets of each health benefits fund;

(f) to determine whether a registered organisation is, or is about to be, in breach of a condition referred to in section 73bab (in this section called a ‘minimum reserve condition’);

(g) where the Council determines that a registered organisation is, or is about to be, in breach of a minimum reserve condition:

(i) to consult with the organisation; and

(ii) to make recommendations to the Minister about the action to be taken, including, where appropriate, a recommendation that the Minister apply under section 82z for the judicial management or winding up of the fund concerned;

(h) to impose levies on each registered organisation, to be calculated on the basis of the number of members of each organisation, for the purpose of meeting the:

(i) general administrative costs of the Council; and

(ii) administrative costs of reviews conducted by Acute Care Advisory Committees under section 3b of the *Health Insurance Act 1973*;

(j) in the event of a registered organisation being unable to meet its liabilities to its members—to impose a levy on each other registered organisation, to be calculated on the basis of the number of their members, for the purpose of helping to meet those liabilities;

(k) where it is necessary, for the purpose of making a proper examination of the financial affairs of a registered organisation, for the Council to incur unusually high costs—to impose an appropriate fee on the organisation concerned;

(m) to make statistics, and other financial information, relating to a registered organisation or registered organisations, publicly available in accordance with the Council’s rules;

(n) to receive applications from registered organisations for review of certificates given under subsection 3b (1) of the *Health Insurance Act 1973* and to refer the applications to the Secretary;

(p) to impose fees in relation to applications for review of certificates given under subsection 3b (1) of the *Health Insurance Act 1973*;

(q) to make recommendations to the Minister in relation to applications made by registered organisations under section 73bac seeking exemption from the minimum reserve conditions;

(r) to make rules, not inconsistent with this Act, for the purpose of the performance of its functions and the exercise of its powers;

(s) to advise the Minister about the financial operations and affairs of registered organisations;

(t) functions incidental to any other functions of the Council; and

(u) any other functions conferred on the Council by this, or any other, Act.

**Powers**

“82h. The Council has power to do all things necessary or convenient to be done for, or in connection with the performance of its functions.

**Directions by Minister**

“82j. (1) The Minister may, by notice in writing to the Commissioner, give directions with respect to the performance of the Council’s functions or the exercise of its powers, and the Council shall comply with any such direction.

“(2) Before giving a direction under subsection (1), the Minister shall consult the Council about the proposed direction.

“(3) The Minister shall cause a copy of each direction to be laid before each House of the Parliament within 15 sitting days of the House after the direction is given.

**Examination of records, books and accounts of registered organisations**

“82k. (1) Where, in the opinion of the Commissioner it is desirable, for the proper performance of the Council’s functions that the records, books and accounts of a registered organisation be examined, the Commissioner may, by signed instrument, authorise:

(a) the Director;

(b) a member of staff of the Council; or

(c) a consultant engaged by the Council;

to examine and report on those records, books and accounts.

“(2) The person authorised under subsection (1) shall, at all reasonable times, have full and free access to any premises in which the records, books and accounts are kept and may take extracts from, or make copies of, the records, books and accounts.

“(3) The Commissioner may, by written notice given to a person who is or has been an officer, servant or agent of a registered organisation, require that person:

(a) to give the Council, within the time specified in the notice, such information relating to the affairs of the registered organisation as is stated by the notice to be required;

(b) to attend, at a time and place specified in the notice, before the Council and give evidence relating to the affairs of the registered organisation; or

(c) to produce, at a time and place specified in the notice, all records, books and accounts in the person’s custody or under the person’s control relating to the affairs of the registered organisation.

“(4) The Commissioner may require the information or evidence, to be given on oath and either orally or in writing and, for that purpose, the Commissioner, or a person authorised in writing by the Commissioner to do so, may administer an oath or affirmation.

“(5) A person shall not:

(a) refuse or fail to comply with a requirement contained in a notice served on the person under subsection (3); or

(b) refuse to be sworn or to make an affirmation.

Penalty: $1,000 or imprisonment for 6 months, or both.

“(6) In this section:

‘registered organisation’ includes an organisation the registration of which was cancelled under section 79 within 12 months before the date of the notice under subsection (3).

**Registered organisation to give information to the Council annually**

“82l. (1) A registered organisation which makes any report to all or any of its members at any time after 30 June 1989, shall, within one month after making the report or within such further time as the Council allows, give a copy of the report to the Council.

“(2) A registered organisation shall, within 3 months after the end of each year commencing with the year ending on 30 June 1989, or within such further time as the Council allows give to the Council:

(a) such financial accounts and statements in respect of that year as the Council requires to be given for use in preparing the report referred to in section 82pa; and

(b) such other statements in respect of that year as are required by the Council’s rules;

certified on behalf of the organisation in accordance with the Council’s rules to be true and correct.

Penalty: $1,000.

**Registered organisation to comply with Council’s reporting requirements**

“82m. It is a condition of registration of a registered organisation that the organisation comply, within a reasonable time, with such requirements as the Council, in the performance of its functions, imposes on the organisation.

**“*Division 4*—*Administration***

**Meetings of Council**

“82n. (1) Subject to subsection (2), the Commissioner shall convene a meeting of the Council when:

(a) the Commissioner thinks it necessary for the efficient performance of the Council’s functions; or

(b) directed to do so by written notice of the Minister.

“(2) The Commissioner shall convene a meeting at least once every 6 months.

“(3) The Commissioner shall determine the time and place at which a meeting is to be held.

“(4) At a meeting, the Commissioner and 2 other members constitute a quorum.

“(5) The Commissioner shall preside at all meetings.

“(6) Questions arising at a meeting shall be determined by the Commissioner, having regard to the advice of the members present.

“(7) Subject to this section, the Commissioner shall determine the procedure of the meeting.

**Delegation by Council**

“82p. The Council may, by writing under its common seal, delegate to:

(a) the Director; or

(b) another member of staff of the Council;

all or any of the functions and powers of the Council.

**Annual report by Council**

“82pa. (1) The Council shall, as soon as practicable after 30 September in each year give the Minister a report on the operations of registered organisations during the year ending on 30 June in that year.

“(2) The report shall include, in respect of each health benefits fund conducted by a registered organisation during the year to which the report relates, the following information in respect of the fund:

(a) contributions payable to the fund;

(b) other amounts payable to the fund;

(c) fund benefits payable out of the fund;

(d) management expenses;

(e) other amounts payable out of the fund;

(f) the balance of the fund as at the end of that year;

(g) details of how the reserves of the fund have been invested;

(h) such other information as the Minister requires to be included.

“(3) The Minister shall lay each report under this section before each House of the Parliament within 15 sitting days of that House after it is received by the Minister.

**“*Division 5*—*Offices of Members***

**Validity of appointments**

“82pb. The appointment of a person as Commissioner or as another member is not invalid because of a defect or irregularity in connection with the person’s appointment.

**Acting Commissioner**

“82pc. (1) The Minister may appoint a person to act as Commissioner:

(a) during a vacancy in the office of Commissioner (whether or not an appointment has been previously made to the office); or

(b) during any period, or during all periods, when the Commissioner is absent from duty or from Australia or is, for any other reason, unable to perform the duties of the office;

but a person appointed to act during a vacancy shall not continue to act for more than 12 months.

“(2) Anything done by or in relation to a person purporting to act as Commissioner is not invalid because:

(a) the occasion for the appointment had not arisen;

(b) there was a defect or irregularity in connection with the appointment;

(c) the appointment had ceased to have effect; or

(d) the occasion for the person to act as Commissioner had not arisen or had ceased.

**Deputies of members**

“82pd. (1) The Minister may appoint a person to be the deputy of a member (other than the Commissioner) in accordance with the guidelines.

“(2) The deputy of a member may attend meetings of the Council that the member does not attend and shall, while attending such a meeting, be taken to be a member.

“(3) Anything done by or in relation to a deputy purporting to act under this section is not invalid because:

(a) there was a defect or irregularity in connection with the appointment; or

(b) the appointment had ceased to have effect.

**“*Division 6*—*Conditions of Members***

**Remuneration and allowances of members**

“82pe. Subject to the *Remuneration Tribunal Act 1973*,a member shall be paid:

(a) such remuneration as is determined by the Remuneration Tribunal; and

(b) such allowances as are prescribed.

**Resignation**

“82pf. A member or a deputy may resign by writing signed and given to the Minister.

**Termination of appointment**

“82pg. (1) The Minister may terminate the appointment of a member or a deputy for misbehaviour or physical or mental incapacity.

“(2) If:

(a) a member or a deputy becomes bankrupt, applies to take the benefit of a law for the relief of bankrupt or insolvent debtors, compounds with his or her creditors or makes an assignment of his or her remuneration for their benefit; or

(b) a member of the Council is absent, except with the leave of the Commissioner, from 3 consecutive meetings of the Council;

the Minister shall terminate the appointment of the member or deputy.

**“*Division 7—Director and Staff***

**Director**

“82ph. (1) There shall be a Director of the Council who shall be appointed by the Council.

“(2) The Council may:

(a) determine the terms and conditions of service of the Director in respect of matters not provided for by this Part; and

(b) at any time terminate such an appointment.

“(3) The Director holds office on a full-time basis.

“(4) Subject to this section, the Director holds office for the period, and subject to the terms and conditions, specified in the instrument of appointment.

“(5) A person who has attained the age of 65 years shall not be appointed as Director.

“(6) A person shall not be appointed as Director for a period that extends beyond the day on which the person will attain the age of 65 years.

“(7) The appointment of a person as Director is not invalid because of a defect or irregularity in connection with the person’s appointment.

**Duties of Director**

“82pj. (1) The Director shall, to the extent determined by the Council, manage the affairs of the Council.

“(2) The Director shall, in managing the affairs of the Council, act in accordance with the policy of, and with any directions given by, the Council.

**Conflict of interests**

“82pk. (1) The Director shall not be present at a meeting of the Council when the Council is making a decision in relation to the office of Director.

“(2) Where the Director has a direct or indirect pecuniary interest in a matter related to his or her duties as Director, he or she shall disclose the nature of the interest to the Commissioner as soon as possible after the relevant facts have come to his or her knowledge.

**Staff and consultants**

“82pl. (1) The Council may employ such staff as the Council thinks necessary to employ to assist the Council in the performance of its functions and the exercise of its powers.

“(2) The Commissioner may arrange with the Secretary of a Department of the Australian Public Service for the services of officers or employees in the Department to be made available to the Council.

“(3) The Council may engage, under agreements in writing, persons having suitable qualifications and experience to perform services as consultants to the Council.

“(4) The terms and conditions of staff employed, or consultants engaged, by the Council are such as are determined by the Council from time to time.

**Remuneration and allowances of Director**

“82pm. Subject to the *Remuneration Tribunal Act 1973*,the Director shall be paid:

(a) such remuneration as is determined by the Remuneration Tribunal; and

(b) such allowances as are prescribed.”.

**Investigation of organisation by inspector**

**46.** Section 82r of the Principal Act is amended by omitting paragraph (1) (a).

**Application for judicial management or winding up of a fund**

**47.** Section 82z of the Principal Act is amended:

**(a)** by omitting subsection (1) and substituting the following subsection:

“(1) Where the Minister, after consideration of:

(a) a report made under section 82w on the completion or termination of an investigation of a registered organisation; or

(b) any recommendation of the Council about the action to be taken in relation to the organisation;

is of the opinion that it is necessary or proper to do so, the Minister may apply to the Court for an order for the fund, or one or more of the funds, conducted by the organisation be placed under judicial management or be wound up.”;

**(b)** by omitting from paragraph (2) (b) “or” (last occurring);

**(c)** by adding at the end of subsection (2) the following word and paragraph:

“; or (d) the Council’s rules.”.

**Merger of funds**

**48.** Section 82zp of the Principal Act is amended by omitting from subsection (1) all words from and including “proposing” to and including “Territory,” and substituting:

“proposing:

(a) the transfer to a fund conducted by one of the organisations in a State or the Northern Territory of the business of the fund or funds conducted by the other organisation or organisations in that State or Territory; or

(b) where one of the organisations has not begun to conduct a fund in a particular State or the Northern Territory—the transfer to that organisation of the business of the fund or funds conducted by the other organisation or organisations in that State or Territory;

being a transfer in accordance with a scheme specified in the application.”.

**Application for review by Tribunal**

**49.** Section 105ab of the Principal Act is amended:

**(a)** by omitting from subsection (1a) “for registration of the organisation”;

**(b)** by omitting subsections (5) and (6) and substituting the following subsection:

“(5) An application may be made to the Tribunal for review of a decision of the Minister under subsection 78 (4).”.

**Officers to observe secrecy**

**50.** Section 135a of the Principal Act is amended:

**(a)** by inserting after subsection (4) the following subsection:

“(4a) Nothing in this section prohibits the Council from publishing under paragraph 82g (m) statistics or financial information relating to a registered organisation or registered organisations.”;

**(b)** by inserting after subsection (12) the following subsection:

“(12a) Where information referred to in subsection (1) is information acquired in the performance of functions or duties, or in the exercise of powers, under Part VIaa, this section applies as if a reference to the Secretary were a reference to the Commissioner of the Private Health Insurance Administration Council.”.

**51.** The Principal Act is amended by inserting the following section after section 138:

**Telephone access to offices**

“138a. The Minister shall direct the Secretary to make provision for the development of a service which will enable a person to make a telephone call to an office that is under the general control of the Secretary, at no greater cost than the cost of a local telephone call.”.

**Regulations**

**52.** Section 140 of the Principal Act is amended by adding at the end the following subsection:

“(2) The regulations may provide that a specified provision of the Act relating to the basic table does not apply, or applies with specified modifications, in respect of:

(a) a specified registered health benefits organisation; or

(b) a specified registered health benefits organisation in the conduct of its business in a specified State or in the Northern Territory.”.

**Schedule**

**53.** **(1)** The Schedule to the Principal Act is amended:

**(a)** by omitting paragraph (a) of the CONDITIONS OF REGISTRATION OF AN ORGANISATION;

**(b)** by omitting from paragraph (1) of those conditions all words after “benefits” (first occurring) and before “who”;

**(c)** by adding at the end of subparagraph (1) (i) “or”;

**(d)** by omitting subparagraph (1) (ii);

**(e)** by adding at the end of paragraph (1) of those conditions:

“; and those contributors shall:

(iv) only be affected by any waiting periods that applied to them for the purposes of the fund from which they transferred; and

(v) have the same entitlements to benefits that they would have had if they had been members of the fund to which they transferred for the period for which they were members of the fund from which they transferred, being benefits of a kind available to members of the fund to which they transferred.”.

**(2)** The Schedule to the Principal Act is amended by omitting from paragraph (d) “of a kind referred to in paragraph (a) or (d)” and substituting “for which a benefit is payable under paragraph (a), (d), (db) or (dc)”.

**Saving**

**54.** A determination for the purposes of subparagraph (db) (i) or (dc) (i) of the definition of “basic private table” or “basic table” in subsection 4 (1) of the Principal Act as in force immediately before the commencement of section 21 (in this section called the “relevant definition”) continues to have effect, and may be revoked, amended or varied, as if it were:

(a) in the case of a determination for the purposes of subparagraph (db) (i) of the relevant definition—a determination under paragraph 4d (1) (a) of the Principal Act as amended by this Act; or

(b) in the case of a determination for the purposes of subparagraph (dc) (i) of the relevant definition—a determination under paragraph 4d(1) (b) of the Principal Act as amended by this Act.

**PART 5—AMENDMENTS OF THE NURSING HOMES ASSISTANCE ACT 1974**

**Principal Act**

**55.** In this Part, “Principal Act” means the *Nursing Homes Assistance Act 1974*4*.*

**Interpretation**

**56.** Section 3 of the Principal Act is amended:

**(a)** by inserting in the definition of “nursing home care” in subsection (1) “, personal care” after “accommodation”;

**(b)** by inserting in subsection (1) the following definition:

“ ‘personal care’ means assistance of a personal nature given to help a person attend to his or her daily needs or carry out his or her daily routine;”.

**Approval in principle of nursing home etc.**

**57.** Section 3a of the Principal Act is amended by inserting after subsection (3) the following subsection:

“(3a) After the commencement of this subsection, the Minister shall not give a certificate under subsection (2) or (3).”.

**Approval of nursing home**

**58.** Section 4 of the Principal Act is amended:

**(a)** by omitting from subparagraph (6) (c) (i) “or”;

**(b)** by inserting after subparagraph (6) (c) (i) the following subparagraph:

“(ia) ensuring that, to the extent that the principles and objectives formulated by the Minister under section 5 of the *Disability Services Act 1986* are applicable in relation to the provision to qualified nursing home patients in the nursing home of:

(a) nursing home care; or

(b) any services that, as specified in the agreement entered into under section 15 by the Commonwealth with the proprietor of the nursing home, are to be provided for qualified nursing home patients in the nursing home;

that care and those services are provided in a manner that furthers those principles and objectives; or”;

**(c)** by adding at the end the following subsections:

“(13) Subject to subsection (14), the Minister shall not, after the commencement of this subsection, grant an approval under this section.

“(14) The Minister may, not later than 30 June 1992, on application made under subsection (1), grant an approval under this section if:

(a) the applicant is the holder of a certificate in force under section 3a in respect of the premises to which the application relates; or

(b) the application relates to premises in respect of which an approval previously granted under this section is in force at the time when the application is made.

“(15) After the commencement of this subsection, the Minister may not determine under subsection (10) a period ending after 30 June 1992.

“(16) If, before the commencement of this subsection, the Minister had determined under subsection (10) a period ending after 30 June 1992, the period so determined shall, for the purposes of this Act, be taken to be a period ending at the end of 30 June 1992.”.

**Application of National Health Act**

**59.** Section 5 of the Principal Act is amended:

**(a)** by omitting from paragraph (1) (a) “and” (last occurring);

**(b)** by inserting after paragraph (1) (a) the following paragraph:

“(ab) section 40ab of the *National Health Act 1953* has also effect after the commencement of this paragraph as if:

(i) any reference in subsections (2) and (3) to a person’s needing or requiring nursing care by reason of infirmity or illness, disease, incapacity or disability were a reference to that person’s needing or requiring

nursing care or personal care by reason of that person’s condition as a disabled person; and

(ii) subsection (4) were omitted and the following subsection substituted:

‘(4) The Minister shall not approve an application under subsection (3) on behalf of a patient if the Minister is satisfied that:

(a) having regard to the medical condition of the patient and to any other relevant circumstances, the needs of the patient would be adequately, and more suitably, provided for in a place other than an approved nursing home; and

(b) accommodation in such a place is available to the patient’; and”.

**Approval of additional services**

**60.** Section 6 of the Principal Act is amended:

**(a)** by omitting paragraph (4) (b) and substituting the following paragraph:

“(b) any other conditions determined by the Minister for the purpose of ensuring:

(i) that the needs of persons of that class who seek the services are satisfactorily provided for; or

(ii) that, to the extent that the principles and objectives formulated by the Minister under section S of the *Disability Services Act 1986* are applicable to the provision of those services for persons of that class, the services are provided in a manner that furthers those principles and objectives.”;

**(b)** by adding at the end the following subsection:

“(7) At the end of 30 June 1992, any approval then in force under this section ceases to be in force.”.

**Common form of nursing home agreement**

**61.** Section 12 of the Principal Act is amended:

**(a)** by omitting subsection (la) and substituting the following subsection:

“(la) In this section:

‘adjusted deficit’, in relation to the proprietor of an approved nursing home, in respect of a year or any other period, means the amount obtained by deducting from the amount that, under subsection (4), is the approved deficit of the proprietor in respect of that year or other period any approved

expenditure by the proprietor in respect of that year or other period that is of one of the following kinds:

(a) expenditure on the replacement of an asset of the nursing home exceeding $1,200 in value;

(b) expenditure exceeding $1,200 on repairs, or maintenance work, carried out on an asset of the nursing home;

(c) contributions paid to a superannuation scheme on behalf of persons employed by the proprietor for the purposes of the nursing home;

(d) payments in respect of long service leave entitlements of persons referred to in paragraph (c);

‘approved expenditure’, in relation to the proprietor of a nursing home, means expenditure in accordance with particulars of expenditure or expected expenditure approved by the Secretary under the agreement relating to the nursing home entered into with the proprietor under section 15;

‘relevant association’ means an association that:

(a) represents eligible organisations; and

(b) is specified by the Minister by notice in writing published in the *Gazette* as a relevant association for the purposes of this section.”;

**(b)** by omitting from subsection (4) “an amount” and substituting “, if subsection (4a) does not apply, the amount”;

**(c)** by inserting in subsection (4) “(including approved services)” after “other services” (first occurring);

**(d)** by inserting after subsection (4) the following subsections:

“(4a) If the adjusted deficit of the proprietor of a nursing home in respect of a year, or other period, ending after 30 June 1989 is more than the amount that, under subsection (4b), is the prescribed amount in relation to the proprietor in respect of that year or period:

(a) the amount of the difference between that adjusted deficit and that prescribed amount shall be deducted from the amount that, under subsection (4), is the approved deficit of the proprietor in respect of that year or period; and

(b) the amount obtained shall, for the purposes of this Act, be taken to be the approved deficit of the proprietor in respect of that year or period.

“(4b) The prescribed amount in relation to the proprietor of an approved nursing home in respect of a year, or other period, ending after 30 June 1989 (in this subsection called the ‘later year’ and ‘later period’ respectively) is:

(a) if the average number of beds occupied per day by qualified nursing home patients in the nursing home during the later year or later period is less than the average number of beds occupied per day by qualified nursing home patients in the nursing home during the year, or (if applicable) other period approved by the Secretary under paragraph (2) (a), ending on 30 June 1989:

(i) the amount calculated by using the formula:



where:

**AD** is the adjusted deficit of the proprietor in respect of the year, or other period, ending on 30 June 1989;

**EAS** is so much of the approved expenditure of the proprietor on the provision of approved services at the nursing home in respect of the year, or other period, ending on 30 June 1989 that is not expenditure of a kind referred to in paragraphs (a), (b), (c) and (d) of the definition of ‘adjusted deficit’ in subsection (1a);

**ANB1** is the average number of beds occupied per day by qualified nursing home patients in the nursing home during the year, or other period, ending on 30 June 1989; and

**ANB2** is the average number of beds occupied per day by qualified nursing home patients in the nursing home during the later year or later period; or

(ii) if a determination under subsection (4c) is in force— the amount calculated under subparagraph (i) increased in the manner set out in the determination; or

(b) if paragraph (a) does not apply:

(i) the amount equal to the adjusted deficit of the proprietor in respect of the year, or (if applicable) other period approved by the Secretary under paragraph (2) (a), ending on 30 June 1989; or

(ii) if a determination under subsection (4c) is in force— the amount referred to in subparagraph (i) increased in the manner set out in the determination.

“(4c) If the Minister, having regard to relevant economic indicators, is satisfied that prescribed amounts under subsection (4b)

in respect of a year, or other period, ending after 30 June 1989 should be higher than amounts obtained under subparagraph (4b) (a) (i) or (b) (i), the Minister may, by written notice, determine that, in determining prescribed amounts under subsection (4b) in respect of that year or other period, any amount obtained under either of those subparagraphs should be increased in the manner set out in the determination.”.

**Certain notices to be subject to disallowance**

**62.** Section 36a of the Principal Act is amended by inserting in subsection (1) “12 (4c) or” after “subsection”.

**PART 6—AMENDMENT OF THE REMUNERATION TRIBUNAL ACT 1973**

**Principal Act**

**63.** In this Part, “Principal Act” means the *Remuneration Tribunal Act 1973*5*.*

**Inquiries and determinations by Tribunal**

**64.** **(1)** Section 7 of the Principal Act is amended:

**(a)** by omitting from paragraph (9) (ac) “and”;

**(b)** by inserting after paragraph (9) (ac) the following paragraphs:

“(ad) in the case of remuneration or allowances payable to a person who holds the office of Commissioner of Private Health Insurance Administration, an office of member of the Private Health Insurance Administration Council or the office of Director of that Council—to be paid in accordance with the determination out of funds under the control of that Council;

(ae) in the case of remuneration or allowances payable to a person who holds an office of member of the Acute Care Advisory Committee or an Acute Care Advisory Committee—to be paid in accordance with the determination out of funds under the control of the Private Health Insurance Administration Council; and”.

**(2)** The amendment made by this section only applies in relation to Acute Care Advisory Committees established after the commencement of section 9 of this Act.

**PART 7—AMENDMENTS OF THE STATES GRANTS (NURSE EDUCATION TRANSFER ASSISTANCE) ACT 1985**

**Principal Act**

**65.** In this Part, “Principal Act” means the *States Grants (Nurse Education Transfer Assistance) Act 1985*6*.*

**Interpretation**

**66.** Section 3 of the Principal Act is amended by inserting in subsection (1) the following definitions:

“ ‘first census day’ means:

(a) 31 March; or

(b) if any other day is prescribed for the purposes of this paragraph—that other day;

‘second census day’ means:

(a) 31 August; or

(b) if any other day is prescribed for the purposes of this paragraph—that other day;”.

**Special nurse education transfer grants**

**67.** Section 4 of the Principal Act is amended:

**(a)** by omitting from subparagraph (3) (c) (i) “30 April” and substituting “the first census day”;

**(b)** by omitting from subparagraph (3) (c) (ii) “30 September” and substituting “the second census day”.

**68.** The Principal Act is amended by adding at the end the following section:

**Regulations**

“10. The Governor-General may make regulations, not inconsistent with this Act, prescribing all matters required or permitted by this Act to be prescribed.”.

**SCHEDULE** Section 18

NEW SCHEDULE 1a TO THE HEALTH INSURANCE ACT 1973

SCHEDULE 1a

PATHOLOGY SERVICES TABLE

RULES FOR INTERPRETATION OF THE PATHOLOGY SERVICES TABLE

1. In this Schedule:

“recognised pathologist” means a medical practitioner who, by reason of a determination under section 61, is recognised for the purposes of this Act as a specialist in the speciality of pathology.

2. Where an item includes the symbol “(SP)”, the item relates to a pathology service when rendered by or on behalf of an approved pathology practitioner who is a recognised pathologist other than a pathology service:

(a) rendered pursuant to a request made in the course of the provision of an out-patient service at a recognised hospital;

(b) rendered pursuant to a request made in respect of a person who was, at the time when the request was made, a private patient in a recognised hospital; or

(c) in the rendering of which:

(i) any pathology equipment of a recognised hospital, or a laboratory included in a prescribed class of laboratories, is used; or

(ii) any member of the staff of a recognised hospital, or a laboratory included in a prescribed class of laboratories, participates in the course of that member’s employment with that hospital or laboratory.

3. Where an item includes the symbol “(OP)”, the item shall be taken to relate to a pathology service other than a pathology service:

(a) to which an item that includes the symbol “(SP)” relates; or

(b) to which sub-section 16a (7) applies.

4. For the purposes of rules 2 and 3 each of the following classes of laboratories is a prescribed class of laboratories:

(a) laboratories operated by the Commonwealth;

(b) laboratories operated by a State or an authority of a State;

(c) laboratories operated by the Northern Territory of Australia;

(d) laboratories operated by the Australian Capital Territory Community and Health Service; and

(e) laboratories operated by an Australian tertiary institution.

5. Two or more pathology services rendered pursuant to 2 or more requests shall be taken to have been rendered pursuant to a single request if:

(a) each pathology service is rendered to the same person;

(b) each pathology service is of a kind listed in the one item of the table; and

(c) the determinations of the necessity for the pathology services were made on the same day.

6. In rule 5, “service” includes an assay, estimation or test.

7. A reference in these rules to a request made to an approved pathology practitioner includes a reference to a request that is deemed, for the purposes of section 16a, to have been made to that approved pathology practitioner.

8. Where:

(a) a pathology service (the ‘first pathology service’) is rendered pursuant to a request;

**SCHEDULE—**continued

(b) an item of the table applies to that pathology service;

(c) another pathology service (the ‘second pathology service’) is rendered pursuant to the request; and

(d) the second pathology service is of a kind referred to in the item referred to in paragraph (b);

the second pathology service shall be treated as if it were completely subsumed within the first pathology service.

*Example:* Dr Proctor requests an extended blood grouping test (covered by item 1192) and the test includes a basic blood grouping test (covered by item 1187). Item 1187 is referred to in item 1192. Benefit is payable under item 1192 for the extended blood grouping test but benefit is not payable separately under item 1187 for the basic blood grouping test.

9. For the purposes of Division 1—Haematology:

(a) if pathology services of a kind referred to in item 1187, 1188, 1192 or 1193 are rendered to a person during a period of hospitalisation, the item applies only to the first pathology service of that kind rendered to the person during that person’s hospitalisation; and

(b) tests performed on material stored from a previous patient episode (except tests specified in item 1198 or 1199) in response to a subsequent request are treated as being part of that previous patient episode if the second request is made within 14 days of that previous patient episode.

10. For the purposes of Division 2—Chemical Pathology:

(a) where a pathology service involving the measurement of any substance in urine requires a 24 hour urine collection and/or calculation of a substance/creatinine ratio, that pathology service is treated as including any estimation of creatinine in other fluids necessary for calculation; and

(b) tests performed on material stored from a previous patient episode in response to a subsequent request are treated as being part of that previous patient episode if the second request occurs within 14 days of that previous patient episode.

11. For the purposes of Division 3—Microbiology:

(a) serial examinations or cultures means examinations or cultures requested on the one occasion regardless of whether the materials are received on different days by the approved pathology practitioner and regardless of whether the examinations or cultures were requested on one or more request forms by the treating practitioner; and

(b) tests performed on material which has been stored from a previous patient episode in response to a subsequent request are treated as being part of that previous patient episode if the further request occurs within 14 days of that previous patient episode.

12. For the purposes of Division 4—Immunology:

(a) tests performed on material which has been stored from a previous patient episode in response to a subsequent request are treated as being part of that previous patient episode if the further request occurs within 14 days of that previous patient episode; and

(b) in items 2271, 2274, 2275, 2276, 2277, 2278, 2279 and 2280, the estimation of a single antibody includes qualitative and quantitative assays for that antibody.

13. For the purposes of Division 5—Histopathology:

(a) “biopsy material” means all tissue received by the approved pathology practitioner from any operation or group of operations performed on a patient at the one time other than a bone marrow biopsy; and

**SCHEDULE—**continued

(b) where a pathology service relating to the examination of biopsy material is rendered under an item set out in Division 5 in circumstances where a further pathology service or pathology services specified in an item or items in Division 5 are rendered also in relation to that biopsy material, all those pathology services are treated as one pathology service rendered under the one item appropriate ‘to the pathology services provided.

14. For the purposes of Division 6—Cytopathology, “serial examinations” means examinations requested on the one occasion regardless of whether the materials are received on different days by the approved pathology practitioner and regardless of whether the examinations were requested on one or more request forms by the treating practitioner.

15. Where in these rules provision is made for 2 or more pathology services to be treated as one pathology service, a reference to an appropriate item is a reference to the item which incorporates whichever of the symbols (SP) or (OP) is relevant to the rendering of that pathology service.

16. The lists of abbreviations at the end of the table are provided to allow users of the table to identify and refer to particular pathology services, or particular groups of pathology services, more accurately and more conveniently.

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  | *Division 1*—*Haematology* | $ |
| 1163 | Blood count consisting of erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haemoglobin, platelet count, leucocyte count, reticulocyte count—one or two procedures. SP | 7.35 |
| 1164 | Blood count consisting of erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haemoglobin, platelet count, leucocyte count, reticulocyte count—one or two procedures. OP | 5.55 |
| 1168 | Three or more procedures to which item 1163 applies, including any calculation or measurement of erythrocyte or other indices. SP | 10.00 |
| 1169 | Three of more procedures to which item 1164 applies, including any calculation or measurement of erythrocyte or other indices. OP | 7.50 |
| 1170 | Examination of blood film, with or without differential cell count, or differential cell count with or without examination of blood film, and the performance of any of these additional services—Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, choloroacetate esterase, neutrophil alkaline phosphotase, nitro blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, including any services specified in item 1419. SP | 13.20 |
| 1171 | Examination of blood film, with or without differential cell count, or differential cell count with or without examination of blood film, and the performance of any of these additional services—Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, choloroacetate esterase, neutrophil alkaline phosphotase, nitro | 9.90 |

**SCHEDULE—**continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
|  | blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, including any services specified in item 1420. OP |  |
| 1172 | Full blood examination consisting of items 1168 and 1170. SP | 23.00 |
| 1173 | Full blood examination consisting of items 1169 and 1171. OP | 17.25 |
| 1176 | Erythrocytes, qualitative or quantitative assessment of haemolysis or metabolic enzymes by—erythrocyte autohaemolysis test, erythrocyte fragility test, sugar water test, erythrocyte metabolic enzyme test, heat denaturation test, isopropanol precipitation test, acid haemolysis test, and quantitation of muramidase in serum or urine—one or more procedures. SP | 30.50 |
| 1177 | Erythrocytes, qualitative or quantitative assessment of haemolysis or metabolic enzymes by—erythrocyte autohaemolysis test, erythrocyte fragility test, sugar water test, erythrocyte metabolic enzyme test, heat denaturation test, isopropanol precipitation test, acid haemolysis test, and quantitation of muramidase in serum or urine—one or more procedures. OP | 22.90 |
| 1179 | Tests for the diagnosis of haemoglobinopathy consisting of haemoglobin electrophoresis and two of the following—examination for HbH, quantitation of HbA2 or HbF, including any services specified in items 1163, 1168, 1170 and 1172. SP | 47.50 |
| 1180 | Tests for the diagnosis of haemoglobinopathy consisting of haemoglobin electrophoresis and two of the following—examination for HbH, quantitation of HbA2 or HbF, including any services specified in items 1164, 1169, 1171 and 1173. OP | 35.65 |
| 1181 | Histopathological examination of sections of bone marrow trephine biopsy including where indicated, examination of marrow smears and any special stains and immuno-chemical techniques, including any services specified in items 1163, 1168, 1170, 1172 and 1183. SP | 146.00 |
| 1182 | Histopathological examination of sections of bone marrow trephine biopsy including where indicated, examination of marrow smears and any special stains and immuno-chemical techniques, including any services specified in items 1164, 1169, 1171, 1173 and 1184. OP | 109.50 |
| 1183 | Bone marrow examination of aspirated material including any special stains, immuno-chemical techniques and clot sections where necessary, including any services specified in items 1163, 1168, 1170 and 1172. SP | 106.00 |
| 1184 | Bone marrow examination of aspirated material including any special stains, immuno-chemical techniques and clot sections where necessary, including any services specified in items 1164, 1169, 1171 and 1173. OP | 79.50 |
| 1187 | Blood grouping, including back-grouping when performed—ABO and Rh (D antigen). SP | 12.80 |
| 1188 | Blood grouping, including back-grouping when performed—ABO and Rh (D antigen). OP | 9.60 |
| 1192 | Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—one or more systems, including any services specified in item 1187. SP | 25.50 |
| 1193 | Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—one of more systems, including any services specified in item 1188. OP | 19.15 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 1196 | Blood grouping, including back-grouping when performed, and examination of serum for Rh and other blood group antibodies, including identification and quantitative estimation of any antibodies detected, and including any services specified in items 1163, 1168, 1170 and 1172. SP | 47.50 |
| 1197 | Blood grouping, including back-grouping when performed, and examination of serum for Rh and other blood group antibodies, including identification and quantitative estimation of any antibodies detected, and including any services specified in items 1164, 1169, 1171 and 1173. OP | 35.65 |
| 1198 | Compatibility testing, including all necessary grouping checks of patient and donor, examination for antibodies, identification and, if necessary, quantitative estimation of any antibodies detected and any services specified in items 1163, 1168, 1170, 1172, 1187 and 1196 including all testing performed on any one day. SP | 116.00 |
| 1199 | Compatibility testing, including all necessary grouping checks of patient and donor, examination for antibodies, identification and, if necessary, quantitative estimation of any antibodies detected and any services specified in items 1164, 1169, 1171, 1173, 1188 and 1197 including all testing performed on any one day. OP | 87.00 |
| 1417 | Examination of serum for blood group antibodies including identification and, if necessary, quantitative estimation of any antibodies detected. SP | 21.00 |
| 1418 | Examination of serum for blood group antibodies including identification and, if necessary, quantitative estimation of any antibodies detected. OP | 15.75 |
| 1419 | Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examination of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test) excluding those services specified in items 1170 and 1173—one or more tests. SP | 11.60 |
| 1420 | Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examination of blood | 8.70 |
|  | for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test) excluding those services specified in items 1171 and 1173—one or more tests. OP |  |
| 1521 | Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or one of—fibrinogen degradation products, fibrin monomer or D-dimer—one estimation. SP | 16.00 |
| 1522 | Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or one of—fibrinogen degradation products, fibrin monomer or D-dimer—one estimation. OP | 12.00 |
| 1523 | Two estimations specified in item 1521. SP | 21.00 |
| 1524 | Two estimations specified in item 1522. OP | 15.75 |
| 1525 | Three estimations specified in item 1521. SP | 26.50 |
| 1526 | Three estimations specified in item 1522. OP | 19.90 |
| 1527 | Four or more estimations specified in item 1521. SP | 31.50 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 1528 | Four or more estimations specified in item 1522. OP | 23.65 |
| 1531 | Quantitative assay, by one or more techniques, of plasminogen, antithrombin III, Protein C, Protein S, heparin co-factor II, Euglobulin clot lysis time and test for lupus anticoagulant—one estimation. SP | 31.50 |
| 1532 | Quantitative assay, by one or more techniques, of plasminogen, antithrombin III, Protein C, Protein S, heparin co-factor II, Euglobulin clot lysis time and test for lupus anticoagulant—one estimation. OP | 23.65 |
| 1533 | Four or more estimations specified in item 1531. SP | 100.00 |
| 1534 | Four or more estimations specified in item 1532. OP | 75.00 |
| 1535 | Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance—one or more estimations. SP | 63.00 |
| 1538 | Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance—one or more estimations. OP | 47.25 |
| 1539 | Heparin assay, only when monitoring a patient on subcutaneous heparin or low molecular weight heparin—one or more estimations. SP | 42.00 |
| 1540 | Heparin assay, only when monitoring a patient on subcutaneous heparin or low molecular weight heparin—one or more estimations. OP | 31.50 |
| 1541 | Quantitative assay of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, Passovy factor—one estimation. SP | 42.00 |
| 1542 | Quantitative assay of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, Passovy factor—one estimation. OP | 31.50 |
| 1543 | Two estimations as specified in item 1541. SP | 63.00 |
| 1544 | Two estimations as specified in item 1542. OP | 47.25 |
| 1550 | Three or more estimations as specified in item 1541. SP | 79.00 |
| 1551 | Three or more estimations as specified in item 1542. OP | 59.25 |
|  | *Division 2*—*Chemical pathology* |  |
| 1558 | Quantitative estimation in serum, plasma, urine or any other body fluid, by any method except by reagent strip with or without reflectance meter or electrophoresis of—alanine amino-transferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionized), chloride, cholesterol, creatine kinase, creatine kinase isoenzymes (when not performed as specified in item 1734), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, triglycerides, urate, urea—one estimation. SP | 13.20 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 1559 | Quantitative estimation in serum, plasma, urine or any other body fluid, by any method except by reagent strip with or without reflectance meter or electrophoresis of—alanine amino-transferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionized), chloride, cholesterol, creatine kinase, creatine kinase isoenzymes (when not performed as specified in item 1735), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, triglycerides, urate, urea—one estimation. OP | 9.90 |
| 1560 | Two estimations specified in item 1558. SP | 16.00 |
| 1561 | Two estimations specified in item 1559. OP | 12.00 |
| 1562 | Three estimations specified in item 1558. SP | 18.60 |
| 1563 | Three estimations specified in item 1559. OP | 13.95 |
| 1564 | Four estimations specified in item 1558. SP | 21.00 |
| 1565 | Four estimations specified in item 1559. OP | 15.75 |
| 1569 | Five estimations specified in item 1558. SP | 23.50 |
| 1570 | Five estimations specified in item 1559. OP | 17.65 |
| 1571 | Six or more estimations specified in item 1558. SP | 26.50 |
| 1572 | Six or more estimations specified in item 1559. OP | 19.90 |
| 1575 | Qualitative estimation by any method, except by reagent strip or dipstick of the following urine constituents—bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in serum—one or more estimations. SP | 12.60 |
| 1576 | Qualitative estimation by any method, except by reagent strip or dipstick of the following urine constituents—bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in serum—one or more estimations. OP | 9.45 |
| 1577 | Qualitative estimation by any method except by reagent strip or dipstick of the following faecal constituents—haemoglobin, porphyrins, reducing substances—each estimation, to a maximum of three estimations, taken on separate days. SP | 8.40 |
| 1578 | Qualitative estimation by any method except by reagent strip or dipstick of the following faecal constituents—haemoglobin, porphyrins, reducing substances—each estimation, to a maximum of three estimations, taken on separate days. OP | 6.30 |
| 1579 | Immunological test for human haemoglobin in faeces performed in any twenty eight day period, including chemical test if performed—one estimation—SP | 16.00 |
| 1580 | Immunological test for human haemoglobin in faeces performed in any twenty eight day period, including chemical test if performed—one estimation. OP | 12.00 |
| 1581 | Two or more estimations specified in item 1579. SP | 36.50 |
| 1582 | Two or more estimations specified in item 1580. OP | 27.40 |
| 1583 | Osmolality, estimation by osmometer, in serum or in urine—one or more estimations. SP | 31.50 |

**SCHEDULE—**continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 1584 | Osmolality, estimation by osmometer, in serum or in urine—one or more estimations. OP | 23.65 |
| 1590 | Quantitative estimation of blood gases including tests performed from— pO2, oxygen saturation, pCO2, bicarbonate, pH, and any other measurement (eg. haemoglobin, potassium) or calculation performed on the same specimen by the same instrument or group of instruments— one or more estimation on one specimen. SP. | 43.00 |
| 1591 | Quantitative estimation of blood gases including tests performed from— pO2, oxygen saturation, pCO2, bicarbonate, pH, and any other measurement (eg. haemoglobin, potassium) or calculation performed on the same specimen by the same instrument or group of instruments— one or more estimation on one specimen. OP. | 32.25 |
| 1592 | One or more estimations of blood gases as specified in item 1590 on two or more specimens within any one day. SP | 53.00 |
| 1593 | One or more estimations of blood gases as specified in item 1591 on two or more specimens within any one day. OP | 39.75 |
| 1595 | Calculus, analysis of one or more. SP | 39.00 |
| 1596 | Calculus, analysis of one or more. OP | 29.25 |
| 1598 | Drug or chemical assays—including all qualitative and quantitive tests on blood, urine or other body fluid for a drug or drugs of abuse, including illegal drugs and legally available drugs taken other than in appropriate dosage, ingested or absorbed toxic chemicals including any services specified in items 1712, 1714 and 1716, but excluding the surveillance of sports people and athletes for performance improving substances—one or more assays. SP | 53.00 |
| 1599 | Drug or chemical assays—including all qualitative and quantitive tests on blood, urine or other body fluid for a drug or drugs of abuse, including illegal drugs and legally available drugs taken other than in appropriate dosage, ingested or absorbed toxic chemicals including any services specified in items 1713, 1715 and 1717, but excluding the surveillance of sports people and athletes for performance improving substances—one or more assays. OP | 39.75 |
| 1627 | Drug assays—including all qualitative and quantitive estimations on blood, urine or other body fluid for a drug or drugs of abuse or a therapeutic drug on a sample collected from a patient participating in a drug abuse treatment programme, or being treated for drug effects or under a court order or parole board supervision, but excluding the detection of nicotine and metabolites in smoking withdrawal programs— each assay to a maximum of four assays within any twenty eight day period. SP | 26.50 |
| 1628 | Drug assays—including all qualitative and quantitive estimations on blood, urine or other body fluid for a drug or drugs of abuse or a therapeutic drug on a sample collected from a patient participating in a drug abuse treatment programme, or being treated for drug effects or under a court order or parole board supervision, but excluding the detection of nicotine and metabolites in smoking withdrawal programs— each assay to a maximum of four assays within any twenty eight day period. OP | 19.90 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees—  All States |
|  |  | $ |
| 1712 | Drug assay—quantitative estimation on blood or other body fluid by any method or methods of a drug being used therapeutically for the patient from whom the specimen was taken (excluding antibiotics or antimicrobial chemotherapeutic agents)—one estimation. SP | 26.50 |
| 1713 | Drug assay—quantitative estimation on blood or other body fluid by any method or methods of a drug being used therapeutically for the patient from whom the specimen was taken (excluding antibiotics or antimicrobial chemotherapeutic agents)—one estimation. OP | 19.90 |
| 1714 | Two estimations specified in item 1712. SP | 36.50 |
| 1715 | Two estimations specified in item 1713. OP | 27.40 |
| 1716 | Three or more estimations specified in item 1712. SP | 47.50 |
| 1717 | Three or more estimations specified in item 1713. OP | 35.65 |
| 1726 | Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio or palmitic acid—one or more examinations or estimations. SP | 42.00 |
| 1727 | Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio or palmitic acid—one or more examinations or estimations. OP | 31.50 |
| 1734 | Electrophoresis, quantitative or qualitative of serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, or the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase, including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity, but excluding lipoprotein electrophoresis—one examination. SP | 39.00 |
| 1735 | Electrophoresis, quantitative or qualitative of serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, or the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase, including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity, but excluding lipoprotein electrophoresis—one examination. OP | 29.25 |
| 1736 | Electrophoresis, quantitative or qualitative of concurrently collected, or collected within a twenty eight day period, serum and urine to demonstrate protein classes or presence and amount of paraproteins, including the preliminary quantitation of total protein, albumin and globulin, but excluding lipoprotein electrophoresis—two or more examinations. SP | 58.00 |
| 1737 | Electrophoresis, quantitative or qualitative of concurrently collected, or collected within a twenty eight day period, serum and urine to demonstrate protein classes or presence and amount of paraproteins, including the preliminary quantitation of total protein, albumin and globulin, but excluding lipoprotein electrophoresis—two or more examinations. OP | 43.50 |

**SCHEDULE—**continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees—  All States |
|  |  | $ |
| 1738 | Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-l esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 1752), Haptoglobins, Microalbumin (in proven diabetes mellitus), Transferrin (unless specified in item 1752) and, in the follow up of proven malignancy, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Prostatic Acid Phosphatase (one or more fractions), Prostate specific antigen—quantitative estimation in serum, urine or other body fluid—one estimation. SP | 25.50 |
| 1739 | Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-l esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 1753), Haptoglobins, Microalbumin (in proven diabetes mellitus), Transferrin (unless specified in item 1753) and, in the follow up of proven malignancy, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Prostatic Acid Phosphatase (one or more fractions), Prostate specific antigen—quantitative estimation in serum, urine or other body fluid—one estimation. OP | 19.15 |
| 1740 | Two or more estimations specified in item 1738. SP | 47.50 |
| 1741 | Two or more estimations specified in item 1739. OP | 35.65 |
| 1752 | Iron studies consisting of quantitative analysis of iron, transferrin or iron binding capacity and ferritin. SP | 50.00 |
| 1753 | Iron studies consisting of quantitative analysis of iron, transferrin or iron binding capacity and ferritin. OP | 37.50 |
| 1768 | Serum B12, serum folate—one or more estimations within any twenty eight day period. SP | 31.50 |
| 1769 | Serum B12, serum folate—one or more estimations within any twenty eight day period. OP | 23.65 |
| 1770 | Red cell folate and serum B12 and, if required, serum folate, to a maximum of three estimations in any twelve month period. SP | 57.50 |
| 1771 | Red cell folate and serum B12 and, if required, serum folate, to a maximum of three estimations in any twelve month period. OP | 43.00 |
| 1780 | Vitamins, quantitative estimation in blood, urine or other body fluid, by direct or indirect means, of Vitamins A, Bl, B2, B3, B6, C, and E—one or more estimations within any six month period. SP | 39.00 |
| 1783 | Vitamins, quantitative estimation in blood, urine or other body fluid, by direct or indirect means, of Vitamins A, Bl, B2, B3, B6, C, and E—one or more estimations within any six month period. OP | 29.25 |
| 1786 | Vitamin D or D fractions—one or more estimations. SP | 39.00 |
| 1787 | Vitamin D or D fractions—one or more estimations. OP | 29.25 |
| 1791 | Alcohol, ammonia, angiotensin converting enzyme, neonatal bilirubin (one or more fractions), cholinesterase, cystine (cysteine), hydroxyindoleacetic acid, hydroxyproline, lactate, pyruvate, oxalate, xylose, zinc—one quantitative estimation. SP | 31.50 |
| 1792 | Alcohol, ammonia, angiotensin converting enzyme, neonatal bilirubin (one or more fractions), cholinesterase, cystine (cysteine), hydroxyindoleacetic acid, hydroxyproline, lactate, pyruvate, oxalate, xylose, zinc—one quantitative estimation. OP | 23.65 |
| 1795 | Two or more estimations specified in item 1791. SP | 49.50 |
| 1798 | Two or more estimations specified in item 1792. OP | 37.15 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 1871 | Aluminium, arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium—in blood, urine or other body fluid or tissue—one or more estimations within any six month period. SP | 44.50 |
| 1872 | Aluminium, arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium—in blood, urine or other body fluid or tissue—one or more estimations within any six month period. OP | 33.40 |
| 1895 | Blood lead estimation, other than for occupational health screening purposes, to a maximum of three estimations in any six month period—each estimation. SP | 39.00 |
| 1896 | Blood lead estimation, other than for occupational health screening purposes, to a maximum of three estimations in any six month period—each estimation. OP | 29.25 |
| 1959 | Porphyrins (one or more fractions), Catecholamines (one or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA)—quantitative including any qualitative estimations—one or more estimations. SP | 51.00 |
| 1960 | Porphyrins (one or more fractions), Catecholamines (one or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA)—quantitative including any qualitative estimations—one or more estimations. OP | 38.25 |
| 1963 | Faecal fat—one or more quantitative estimations within any twenty eight day period. SP | 51.00 |
| 1964 | Faecal fat—one or more quantitative estimations within any twenty eight day period. OP | 38.25 |
| 1969 | Solid tissue or tissues excluding blood elements—assay of one or two enzymes. SP | 51.00 |
| 1970 | Solid tissue or tissues excluding blood elements—assay of one or two enzymes. OP | 38.25 |
| 1975 | Assay of three to five enzymes as specified in item 1969. SP | 95.00 |
| 1976 | Assay of three to five enzymes as specified in item 1970. OP | 71.25 |
| 1977 | Assay of six or more enzymes as specified in item 1969. SP | 126.00 |
| 1978 | Assay of six or more enzymes as specified in item 1970. OP | 94.50 |
| 1983 | Thyroid function tests, including thyrotrophin (TSH) and at least one or more of the following tests—free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin. SP | 53.00 |
| 1984 | Thyroid function tests, including thyrotrophin (TSH) and at least one or more of the following tests—free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin. OP | 39.75 |
| 1985 | Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and all necessary estimations of hormones. SP | 63.00 |
| 1986 | Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and all necessary estimations of hormones. OP | 47.25 |

**SCHEDULE—**continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 2021 | Hormones and hormone binding proteins, quantitative estimation by any method of— ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, Cortisol, Cyclic AMP, DHEAS, FSH, Gastrin, Growth hormone, Hydroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin (anti diuretic hormone)—one estimation. SP | 36.50 |
| 2024 | Hormones and hormone binding proteins, quantitative estimation by any method of—ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, Cortisol, Cyclic AMP, DHEAS, FSH, Gastrin, Growth hormone, Hydroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin (anti diuretic hormone)—one estimation. OP | 27.40 |
| 2025 | Two estimations specified in item 2021. SP | 58.00 |
| 2026 | Two estimations specified in item 2024. OP | 43.50 |
| 2027 | Three estimations specified in item 2021. SP | 73.00 |
| 2028 | Three estimations specified in item 2024. OP | 54.75 |
| 2029 | Four estimations specified in item 2021. SP | 89.00 |
| 2030 | Four estimations specified in item 2024. OP | 66.75 |
| 2031 | Five estimations specified in item 2021. SP | 100.00 |
| 2032 | Five estimations specified in item 2024. OP | 53.45 |
| 2033 | Six or more estimations specified in item 2021. SP | 112.00 |
| 2034 | Six or more estimations specified in item 2024. OP | 84.00 |
| 2037 | Hormone receptor assay on proven primary breast carcinoma or subsequent lesion in the breast or metastasis from a breast carcinoma— one or more assays. SP | 102.00 |
| 2038 | Hormone receptor assay on proven primary breast carcinoma or subsequent lesion in the breast or metastasis from a breast carcinoma— one or more assays. OP | 76.50 |
| 2039 | HDL cholesterol, estimation of, in patients, with serum cholesterol >5.5mmol/l—each estimation to a maximum of four estimations in any twelve month period. SP | 16.00 |
| 2040 | HDL cholesterol, estimation of, in patients, with serum cholesterol >5.5mmol/l—each estimation to a maximum of four estimations in any twelve month period. OP | 12.00 |
| 2043 | Glycosylated haemoglobin only when performed in the management of established diabetes—each estimation to a maximum of four estimations in any twelve month period. SP | 21.50 |
| 2044 | Glycosylated haemoglobin only when performed in the management of established diabetes—each estimation to a maximum of four estimations in any twelve month period. OP | 16.15 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
|  | *Division 3*—*Microbiology* |  |
| 2083 | Microscopic examination including serial examinations of material other than blood, from one or more sites, obtained directly from a patient and excluding material from cultures—wet film, including differential cell count if performed, examination for dermatophytes or dark ground illumination, of stained preparation or preparations using any relevant stain or stains—one or more examinations. SP | 9.50 |
| 2084 | Microscopic examination including serial examinations of material other than blood, from one or more sites, obtained directly from a patient and excluding material from cultures—wet film, including differential cell count if performed, examination for dermatophytes or dark ground illumination, or stained preparation or preparation using any relevant stain or stains—one or more examinations. OP | 7.15 |
| 2085 | Microscopic examination of faeces for parasites using concentration techniques including the use of appropriate stains, to a maximum of three estimations taken on separate days including any services specified in item 2083—each estimation. SP | 16.00 |
| 2086 | Microscopic examination of faeces for parasites using concentration techniques including the use of appropriate stains, to a maximum of three estimations taken on separate days including any services specified in item 2084—each estimation. OP | 12.00 |
| 2087 | The cultural examination and miscroscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic microorganisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any services specified in item 2083, 2089 and 2098—one or more sites. SP | 25.00 |
| 2088 | The cultural examination and miscroscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic microorganisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any services specified in item 2084, 2090 and 2099—one or more sites. OP | 18.75 |
| 2089 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from the following sites—skin or other superficial sites, urethral, vaginal, cervical, sputum (except when part of item 2119) and rectal (except for faecal pathogens), including pathogenic identification and antibiotic sensitivity testing, including any services specified in item 2083, 2087 and 2098—one or more sites. SP | 36.50 |
| 2090 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from the following sites—skin or other superficial sites, urethral, vaginal, cervical, sputum (except when part of item 2120) and rectal (except for faecal pathogens), including pathogenic identification and antibiotic sensitivity testing, including any services specified in item 2084, 2088 and 2099—one or more sites. OP | 27.40 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 2098 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of post-operative wounds, aspirations of body cavities, synovial fluid CSF and operative or biopsy specimens for the presence of pathogenic micro-organisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any services specified in item 2083, 2087 and 2089—one or more sites. SP | 49.50 |
| 2099 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of post-operative wounds, aspirations of body cavities, synovial fluid CSF and operative or biopsy specimens for the presence of pathogenic micro-organisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any services specified in item 2084, 2088 and 2090—one or more sites. OP | 37.15 |
| 2117 | Cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of faeces to determine the presence or absence of faecal pathogens, involving the use of at least two selective or enrichment media as well as culture in at least two different atmospheres and includes pathogen identification and antibiotic sensitivity testing, including any services specified in item 2083, to a maximum of three specimens in any seven day period—each examination. SP | 60.00 |
| 2118 | Cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of faeces to determine the presence or absence of faecal pathogens, involving the use of at least two selective or enrichment media as well as culture in at least two different atmospheres and includes pathogen identification and antibiotic sensitivity testing, including any services specified in item 2084, to a maximum of three specimens in any seven day period—each examination. OP | 45.00 |
| 2119 | Microscopy with appropriate stains and cultural examinations of three specimens of sputum, urine or other bodily fluids for mycobacteria and any other bacterial pathogens, including pathogen identification and antibiotic sensitivity testing and including any services specified in item 2083. SP | 84.00 |
| 2120 | Microscopy with appropriate stains and cultural examinations of three specimens of sputum, urine or other bodily fluids for mycobacteria and any other bacterial pathogens, including pathogen identification and antibiotic sensitivity testing and including any services specified in item 2084. OP | 63.00 |
| 2123 | Blood culture to determine the presence or absence of pathogenic micro-organisms excluding viruses, including serial cultures and subcultures, any relevant cultural methods and any tests necessary to identify any cultured pathogen and necessary antibiotic sensitivity testing—each set of cultures to a maximum of three sets. SP | 22.00 |

**SCHEDULE—**continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 2124 | Blood culture to determine the presence or absence of pathogenic micro-organisms excluding viruses, including serial cultures and subcultures, any relevant cultural methods and any tests necessary to identify any cultured pathogen and necessary antibiotic sensitivity testing—each set of cultures to a maximum of three sets. OP | 16.50 |
| 2127 | Urine examination including serial examination, with cell count, relevant stained preparations, culture, colony count by any method, identification of any cultured pathogens, antibiotic sensitivity testing when necessary, and with any relevant general examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts. (Simple culture by dip slide is excluded from this item). SP | 26.50 |
| 2128 | Urine examination including serial examination, with cell count, relevant stained preparations, culture, colony count by any method, identification of any cultured pathogens, antibiotic sensitivity testing when necessary, and with any relevant general examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts. (Simple culture by dip slide is excluded from this item). OP | 19.90 |
| 2129 | Direct detection of the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus (in CSF and urine specimens only), RSV, cryptococcal antigens and Varicella Zoster—one or more estimations. SP | 21.00 |
| 2130 | Direct detection of the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus (in CSF and urine specimens only), RSV, cryptococcal antigens and Varicella Zoster—one or more estimations. OP | 15.75 |
| 2133 | Direct detection of Chlamydia from clinical material, not cultures— one or more estimations. SP | 12.60 |
| 2134 | Direct detection of Chlamydia from clinical material, not cultures— one or more estimations. OP | 9.45 |
| 2135 | Direct detection of Herpes simplex from clinical material, not cultures— one or more estimations. SP | 12.60 |
| 2136 | Direct detection of Herpes simplex from clinical material, not cultures— one or more estimations. OP | 9.45 |
| 2139 | Investigation for Herpes simplex virus (one or more types) or Chlamydia trachomatis, in material obtained directly from a patient, by one or more cultural methods, including any services specified in items 2133 and 2135. SP | 36.50 |
| 2140 | Investigation for Herpes simplex virus (one or more types) or Chlamydia trachomatis, in material obtained directly from a patient, by one or more cultural methods, including any services specified in items 2134 and 2136. OP | 27.40 |
| 2145 | Serology including IgG and IgM estimations of Rubella, toxoplasma or CMV when performed during pregnancy—one or more assays. SP | 17.80 |
| 2146 | Serology including IgG and IgM estimations of Rubella, toxoplasma or CMV when performed during pregnancy—one or more assays. OP | 13.35 |
| 2181 | Antibodies to microbial or exogenous antigens not elsewhere specified in the Schedule—estimation of one antibody. SP | 17.80 |
| 2182 | Antibodies to microbial or exogenous antigens not elsewhere specified in the Schedule—estimation of one antibody. OP | 13.35 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 2183 | Two estimations specified in item 2181. SP | 27.50 |
| 2184 | Two estimations specified in item 2182. OP | 20.65 |
| 2185 | Three estimations specified in item 2181. SP | 36.50 |
| 2186 | Three estimations specified in item 2182. OP | 27.40 |
| 2187 | Four estimations specified in item 2181. SP | 46.00 |
| 2188 | Four estimations specified in item 2182. OP | 34.50 |
| 2189 | Five estimations specified in item 2181. SP | 56.00 |
| 2190 | Five estimations specified in item 2182. OP | 42.00 |
| 2191 | Six or more estimations specified in item 2181. SP | 65.00 |
| 2192 | Six or more estimations specified in item 2182. OP | 48.75 |
| 2221 | Hepatitis B surface antigen test. SP | 17.80 |
| 2222 | Hepatitis B surface antigen test. OP | 13.35 |
| 2223 | Hepatitis B serology to define the immune status of an individual, including at least Hepatitis B surface antibody or Hepatitis B core antibody tests, including services specified in items 2221, 2229 and 2231. SP | 24.00 |
| 2224 | Hepatitis B serology to define the immune status of an individual, including at least Hepatitis B surface antibody or Hepatitis B core antibody tests, including services specified in items 2222, 2230 and 2232. OP | 18.00 |
| 2229 | All serological tests performed for the identification of the agent causing acute hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core IgM antibody and Hepatitis A IgM antibody tests and those services specified in items 2221, 2223 and 2232. SP | 47.50 |
| 2230 | All serological tests performed for the identification of the agent causing acute hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core IgM antibody and Hepatitis A IgM antibody tests and those services specified in items 2222, 2224 and 2232. OP | 35.65 |
| 2231 | All tests performed in the follow up of a patient with proven Hepatitis B, including Hepatitis B surface antigen and either Hepatitis Be antigen or Hepatitis B surface antibody tests, including services specified in items 2221 and 2223. SP | 34.50 |
| 2232 | All tests performed in the follow up of a patient with proven Hepatitis B, including Hepatitis B surface antigen and either Hepatitis Be antigen of Hepatitis B surface antibody tests, including services specified in items 2222 and 2224. OP | 25.90 |
| 2235 | Antibiotics or anti-microbial chemo-therapeutic agents, concentration in serum, urine or other body fluid, by direct quantitative measurement of the agent—one or more estimations. SP | 31.50 |
| 2236 | Antibiotics or anti-microbial chemo-therapeutic agents, concentration in serum, urine or other body fluid, by direct quantitative measurement of the agent—one or more estimations. OP | 23.65 |
|  | *Division 4*—*Immunology* |  |
| 2239 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1734, 1736 or 2245), on serum, urine or other body fluid, or examination of CSF for oligoclonal proteins by immunoelectrophoresis or immunofixation—one or more procedures. SP | 39.00 |

**SCHEDULE—**continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 2240 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1735, 1737 or 2246), on serum, urine or other body fluid, or examination of CSF for oligoclonal proteins by immunoelectrophoresis or immunofixation—one or more procedures. OP | 29.25 |
| 2241 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1734, 1736 or 2245), on serum and urine concurrently collected—two or more procedures. SP | 58.00 |
| 2242 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1735, 1737 or 2246), on serum and urine concurrently collected—two or more procedures. OP | 43.50 |
| 2245 | Immunoglobulins G, A, M or D, quantitative estimation in serum, urine or other body fluid, by any method—estimation of one immunoglobin. SP | 19.00 |
| 2246 | Immunoglobulins G, A, M or D, quantitative estimation in serum, urine or other body fluid, by any method—estimation of one immunoglobin. OP | 14.25 |
| 2251 | Two estimations specified in item 2245. SP | 29.50 |
| 2252 | Two estimations specified in item 2246. OP | 22.15 |
| 2253 | Three or more estimations specified in item 2245. SP | 40.00 |
| 2254 | Three or more estimations specified in item 2246. OP | 30.00 |
| 2255 | Subclasses of Immunoglobulin G, 1 to 4, estimation where there is a reduced level of clinical significance of either total IgG or IgA—one or more estimations. SP | 58.00 |
| 2256 | Subclasses of Immunoglobulin G, 1 to 4, estimation where there is a reduced level of clinical significance of either total IgG or IgA—one or more estimations. OP | 43.50 |
| 2257 | Immunoglobulin E (total), quantitative estimation by any method or methods, with a maximum of two estimations in any twelve month period. SP | 33.50 |
| 2258 | Immunoglobulin E (total), quantitative estimation by any method or methods, with a maximum of two estimations in any twelve month period. OP | 25.19 |
| 2259 | Specific IgG or IgE antibodies to potential allergens—one or more tests for single or multiple allergens with a maximum of four estimations in any twelve month period. SP | 30.50 |
| 2260 | Specific IgG or IgE antibodies to potential allergens—one or more tests for single or multiple allergens with a maximum of four estimations in any twelve month period. OP | 22.90 |
| 2261 | Antinuclear antibodies, detection in serum or other body fluids. SP | 31.50 |
| 2262 | Antinuclear antibodies, detection in serum or other body fluids. OP | 23.65 |
| 2263 | Quantitation of antinuclear antibodies and measurement of DNA binding (by Fair assay), performed only where a positive titre greater than 1 in 10 is obtained including services specified in item 2261. SP | 70.00 |
| 2266 | Quantitation of antinuclear antibodies and measurement of DNA binding (by Farr assay), performed only where a positive titre greater than 1 in 10 is obtained including services specified in item 2262. OP | 52.50 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 2267 | Antibodies to extractable nuclear antigens, detection of in serum or other body fluids. SP | 26.50 |
| 2268 | Antibodies to extractable nuclear antigens, detection of in serum or other body fluids. OP | 19.90 |
| 2269 | Characterization of antibodies to extractable nuclear antigens, performed only where a positive result is obtained including services specified in item 2267. SP | 42.00 |
| 2270 | Characterization of antibodies to extractable nuclear antigens, performed only where a positive result is obtained including services specified in item 2268. OP | 31.50 |
| 2271 | Antibodies to tissue antigens which are not elsewhere specified in an item in the Schedule—estimation of one antibody. SP | 31.50 |
| 2274 | Antibodies to tissue antigens which are not elsewhere specified in an item in the Schedule—estimation of one antibody. OP | 23.65 |
| 2275 | Two estimations specified in item 2271. SP | 36.50 |
| 2276 | Two estimations specified in item 2274. OP | 27.40 |
| 2277 | Three estimations specified in item 2271. SP | 42.00 |
| 2278 | Three estimations specified in item 2274. OP | 31.50 |
| 2279 | Four or more estimations specified in item 2271. SP | 47.50 |
| 2280 | Four or more estimations specified in item 2274. OP | 35.65 |
| 2281 | Rheumatoid factor, detection of by any technique. SP | 12.60 |
| 2282 | Rheumatoid factor, detection of by any technique. OP | 9.45 |
| 2283 | Quantitation of Rheumatoid factor where detected, including services specified in item 2281. SP | 25.00 |
| 2284 | Quantitation of Rheumatoid factor where detected, including services specified in item 2282. OP | 18.75 |
| 2289 | Complement—total and components—one quantitative estimation. SP | 21.00 |
| 2290 | Complement—total and components—one quantitative estimation. OP | 15.75 |
| 2291 | Two estimations as specified in item 2289. SP | 31.50 |
| 2292 | Two estimations as specified in item 2290. OP | 23.65 |
| 2293 | Three or more estimations as specified in item 2289. SP | 42.00 |
| 2312 | Three or more estimations as specified in item 2290. OP | 31.50 |
| 2313 | Leucocyte fractionation as a preliminary to leucocyte marker or leucocyte function tests. SP | 39.00 |
| 2314 | Leucocyte fractionation as a preliminary to leucocyte marker or leucocyte function tests. OP | 29.25 |
| 2315 | Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar and any test specified in the HAEMATOLOGY DIVISION of the Schedule). SP | 66.00 |
| 2316 | Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar and any test specified in the HAEMATOLOGY DIVISION of the Schedule). OP | 49.50 |
| 2317 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques to assess lymphoid populations using a minimum of three monoclonal antibodies, including any services in item 2319—one or more estimations. SP | 84.00 |
| 2318 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques to assess lymphoid populations using a minimum of three monoclonal antibodies, including any services in item 2320—one or more estimations. OP | 63.00 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 2319 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques in the investigation of a probable haematological malignancy using, a minimum of seven monoclonal antibodies, including any services in item 2317—one or more estimations. SP | 200.00 |
| 2320 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques in the investigation of a probable haematological malignancy using, a minimum of seven monoclonal antibodies, including any services in item 2318—one or more estimations. OP | 150.00 |
| 2321 | HLA typing comprising A, B, C and DR phenotypes. SP | 89.00 |
| 2322 | HLA typing comprising A, B, C and DR phenotypes. OP | 66.75 |
| 2323 | HLA typing, excluding any services specified in item 2321—one or more antigens. SP | 36.50 |
| 2324 | HLA typing, excluding any services specified in item 2322—one or more antigens. OP | 27.40 |
| 2325 | Mantoux test. SP | 12.60 |
| 2326 | Mantoux test. OP | 9.45 |
|  | *Division 5*—*Histopathology* |  |
| 2327 | Histopathology examination of biopsy material including all tissue processing, staining and professional opinion or opinions. SP | 89.00 |
| 2328 | Histopathology examination of biopsy material including all tissue processing, staining and professional opinion or opinions. OP | 66.75 |
| 2329 | Immediate frozen section diagnosis of biopsy material, including any other histopathology examination. SP | 166.00 |
| 2330 | Immediate frozen section diagnosis of biopsy material, including any other histopathology examination. OP | 124.50 |
| 2331 | Immunohistochemical investigation of biopsy material by one or more of immunofluorescent, immunoperoxidase or other labelled antibody techniques including any other histopathology examination. SP | 126.00 |
| 2332 | Immunohistochemical investigation of biopsy material by one or more of immunofluorescent, immunoperoxidase or other labelled antibody techniques including any other histopathology examination. OP | 94.50 |
| 2333 | Electron microscopy of biopsy material including any other histopathology examination. SP. | 134.00 |
| 2337 | Electron microscopy of biopsy material including any other histopathology examination. OP. | 100.50 |
|  | *Division 6*—*Cytopathology* |  |
| 2338 | Cytological examination of smears from cervix or vagina for detection of pre-cancerous or cancerous changes—one or more examinations. SP | 19.40 |
| 2339 | Cytological examination of smears from cervix or vagina for detection of pre-cancerous or cancerous changes—one or more examinations. OP | 14.55 |
| 2340 | Cytological examination including serial examinations of smears from skin, nipple discharge, lip, mouth, nose or anus for detection of precancerous or cancerous changes—one or more examinations. SP | 19.40 |
| 2341 | Cytological examination including serial examinations of smears from skin, nipple discharge, lip, mouth, nose or anus for detection of precancerous or cancerous changes—one or more examinations. OP | 14.55 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees—  All States |
|  |  | $ |
| 2343 | Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine, washings or brushings not specified in item 2340 and any histopathological service performed—one or more examinations. SP | 38.00 |
| 2344 | Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine, washings or brushings not specified in item 2341 and any histopathological service performed—one or more examinations. OP | 28.50 |
| 2348 | Cytological examination including examination of a series of three sputum or urine specimens for malignant cells. SP | 79.00 |
| 2349 | Cytological examination including examination of a series of three sputum or urine specimens for malignant cells. OP | 59.25 |
| 2350 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues. SP | 47.50 |
| 2351 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues. OP | 35.65 |
| 2355 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist, or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance. SP | 89.00 |
| 2356 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist, or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance. OP | 66.75 |
|  | *Division 7*—*Cytogenetics* |  |
| 2360 | Chromosome studies, including preparation, count and karyotyping of one or more of amniotic fluid, bone marrow, skin and any other tissue or fluid excluding blood—one or more estimations. SP | 172.00 |
| 2361 | Chromosome studies, including preparation, count and karyotyping of one or more of amniotic fluid, bone marrow, skin and any other tissue or fluid excluding blood—one or more estimations. OP | 129.00 |
| 2363 | Chromosome studies, including preparation, count and karyotyping of blood. SP | 156.00 |
| 2364 | Chromosome studies, including preparation, count and karyotyping of blood. OP | 117.00 |
| 2365 | Chromosome indentification by banding techniques (using fluorescein, Giemsa, or centromere staining of high resolution analysis); or by fragile X-site determination—one or more identifications. SP | 134.00 |
| 2366 | Chromosome indentification by banding techniques (using fluorescein, Giemsa, or centromere staining of high resolution analysis); or by fragile X-site determination—one or more identifications. OP | 100.50 |
|  | *Division 8*—*Infertility and pregnancy tests* |  |
| 2370 | Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test). SP | 8.80 |

**SCHEDULE—**continued

|  |  |  |
| --- | --- | --- |
| Item No. | Pathology Service | Fees— All States |
|  |  | $ |
| 2371 | Semen examination for presence for spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test). OP | 6.60 |
| 2372 | Semen examination, involving measurement of volume, sperm count, motility, examination of stained preparations, morphology, and, if performed, differential count and one or more chemical tests, with a maximum of four examinations in any twelve month period. SP | 36.50 |
| 2373 | Semen examination, involving measurement of volume, sperm count, motility, examination of stained preparations, morphology, and, if performed, differential count and one or more chemical tests, with a maximum of four examinations in any twelve month period. OP | 27.40 |
| 2377 | Sperm antibodies, sperm penetrating ability—one or more tests. SP | 23.50 |
| 2378 | Sperm antibodies, sperm penetrating ability—one or more tests. OP | 17.65 |
| 2379 | Chorionic gonadotrophin (beta—HCG), qualitative estimation in serum or urine by one or more methods, including serial dilution if performed, for diagnosis of pregnancy—one or more estimations. SP | 12.80 |
| 2380 | Chorionic gonadotrophin (beta-HCG), qualitative estimation in serum or urine by one or more methods, including serial dilution if performed, for diagnosis of pregnancy—one or more estimations. OP | 9.60 |
| 2384 | Chorionic gonadotrophin (beta-HCG), qualitative (if performed) and quantitative estimation in serum by one or more methods for diagnosis of hydatidiform mole, HCG—secreting neoplasm, threatened abortion or follow-up of abortion. SP | 36.50 |
| 2385 | Chorionic gonadotrophin (beta-HCG), qualitative (if performed) and quantitative estimation in serum by one or more methods for diagnosis of hydatidiform mole, HCG—secreting neoplasm, threatened abortion or follow-up of abortion. OP | 27.40 |
|  | *Division 9*—*Simple basic pathology tests* |  |
| 2389 | Blood count consisting of leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count) or any or all of haemoglobin estimation, haematocrit estimation or erythrocyte count—one procedure. | 3.90 |
| 2390 | Two procedures specified in item 2389 | 5.85 |
| 2391 | Three or more procedures specified in item 2389 | 7.80 |
| 2393 | Microscopical examination of urine. | 3.90 |
| 2394 | Pregnancy test by one or more immunochemical methods. | 9.60 |
| 2395 | Microscopical examination of wet film other than urine. | 5.85 |
| 1396 | Microscopical examination of gram stained film. | 7.40 |
| 1397 | Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method. | 1.95 |
| 2398 | Microscopical examination screening for fungi in skin, hair or nails— one or more sites. | 5.85 |
| 2399 | Mantoux test. | 9.60 |
| 2400 | Seminal examination for presence of spermatozoa. | 5.85 |

**SCHEDULE**—continued

LISTS OF ABBREVIATIONS

A. ABBREVIATIONS FOR GROUPS OF TESTS

|  |  |  |  |
| --- | --- | --- | --- |
| Group | Estimations  Included in Group | Abbreviation | Item  Numbers |
| Cardiac Enzymes | Lactate dehydrogenase LD,  Aspartate Aminotransferase (AST) and Creatine kinase (CK). | CE | 1562, 1563 |
| Coagulation Studies | Prothrombin time, activated partial thromboplastin time and fibrinogen plus one or more of the following tests-Bleeding time, thrombin clotting time, fibrinogen degradation products, fibrin monomer, D-dimer, Factor XIII screening tests | COAG | 1527, 1528 |
| Electrolytes | Sodium (NA),  Potassium (K),  Chloride (CL) and Bicarbonate (HCO3). | E | 1564, 1565 |
| Lipid Studies | Cholesterol (CHOL) and Triglycerides (TRIG), | FATS | 1560, 1561 |
| Liver Function Tests | Alkaline phosphatase (ALP), Alanine aminotransferase (ALT),  Aspartate aminotransferase (AST),  Albumin (ALB),  Bilirubin (BIL),  Gamma glutamyl transpeptidase (GGT),  Lactate dehydrogenase (LDH) and  Protein (PROT). | LFT | 1571, 1572 |
| Syphilis Serology | Rapid plasma reagin test (RPR) or venereal disease research laboratory test (VDRL) and  Treponema pallidum haemagglutin test (TPHA) or Fluorescent Treponemal antibody-absorpotion test (FTA) | STS | 2183, 2184 |

**SCHEDULE**—continued

B. ABBREVIATIONS FOR INDIVIDUAL TESTS

The abbreviations are listed alphabetically within Divisions. The Divisions are:

HAEMATOLOGY

CHEMICAL PATHOLOGY

MICROBIOLOGY

IMMUNOLOGY

HISTOPATHOLOGY

CYTOPATHOLOGY

CYTOGENETICS

INFERTILITY & PREGNANCY TESTS

|  |  |  |
| --- | --- | --- |
| Approved Item Name of test in Schedule | Abbreviation | Numbers |
| DIVISION 1 HAEMATOLOGY | |  |
| Antithrombin III | ATH | 1531, 1532 |
| Abnormal haemoglobins—spectroscopic examination of blood | AH | 1419, 1420 |
| Bleeding Time | BT | 1521, 1522 |
| Blood coagulation factors—quantitative assays: |  | 1541, 1542 |
| Von Willebrands factor antigen | VWA |
| Von Willebrands factor | VWF | 1541, 1542 |
| Fletcher Factor | FF | 1541, 1542 |
| Fitzgerald Factor | FGF | 1541, 1542 |
| Passovy Factor | PF | 1541, 1542 |
| Factor II | FII | 1541, 1542 |
| Factor V | FV | 1541, 1542 |
| Factor VII | FVII | 1541, 1542 |
| Factor VIII | VIII | 1541, 1542 |
| Factor IX | FIX | 1541, 1542 |
| Factor X | FX | 1541, 1542 |
| Factor XI | FXI | 1541, 1542 |
| Factor XII | FXII | 1541, 1542 |
| Factor XIII | FXIII | 1541, 1542 |
| Blood Film | BF | 1170, 1171 |
| Blood Group Antibodies | BGA | 1417, 1418 |
| Blood Grouping-ABO and RH (D antigen) | BG | 1187, 1188 |
| Blood Group and blood group antibodies (group and hold) | BGAB | 1196, 1197 |
| Blood Group Systems (Duffy, Kell, M&N factors, Rh phenotypes) | BGS | 1192, 1193 |
| Bone Marrow Examination—Threphine | BMET | 1181, 1182 |
| Bone Marrow Examination—Aspirate | BMEA | 1183, 1184 |
| Coagulation Time | CT | 1521, 1522 |
| Cold Agglutinins | CAG | 1419, 1420 |
| Compatibility testing | XMAT | 1198, 1199 |
| C-reactive protein | CRP | 1163, 1164 |
| Differential Cell Count | DIFF | 1170, 1171 |
| Direct Coombs test | CMBS | 1419, 1420 |
| D-dimer test | DD | 1521, 1522 |
| Erythrocyte Count | RCC | 1163, 1164 |
| Erythrocyte Metabolic Enzymes | ERYM | 1176, 1177 |

**SCHEDULE—**continued

|  |  |  |
| --- | --- | --- |
| Approved Item Name of test in Schedule | Abbreviation | Numbers |
| Erythrocyte Sedimentation Rate | ESR | 1163, 1164 |
| Erythrocyte Haemolysis | ERYH | 1176, 1177 |
| Euglobulin clot lysis time | ECLT | 1531, 1532 |
| Fibrinogen Degradation Products | FDP | 1521, 1522 |
| Fibrin Monomer | FM | 1521, 1522 |
| Fibrinogen | FIB | 1521, 1522 |
| Full Blood Examination | FBE | 1172, 1173 |
| Haemoglobin Estimation | HB | 1163, 1164 |
| Haemoglobinopathy tests | HMGP | 1179, 1180 |
| Heparin Cofactor II | HRNC | 1531, 1532 |
| Heparin estimation | HEPR | 1539, 1540 |
| Heterophile Antibodies (Infectious Mononucleosis Test) | IM | 1419, 1420 |
| Leucocyte Count | WCC | 1163, 1164 |
| Lupus Anticoagulant | LUPA | 1531, 1532 |
| Metalbumin detection (Schumm’s test) | SCHM | 1419, 1420 |
| Plasminogen | PLAS | 1531, 1532 |
| Partial Thromboplastin Time | PTT | 1521, 1522 |
| Platelet Aggregation | PLTG | 1535, 1538 |
| Platelet Count | PLTC | 1163, 1164 |
| Protein C | PROC | 1531, 1532 |
| Protein S | PROS | 1531, 1532 |
| Prothrombin Time | PT | 1521, 1522 |
| Red Cell Porphyrins-qualitative test | RCP | 1419, 1420 |
| Reticulocyte Count | RETC | 1163, 1164 |
| Test for Factor XIII deficiency | F13D | 1521, 1522 |
| Thalassaemia Studies | TS | 1179, 1180 |
| Thrombin Time | TT | 1521, 1522 |
| Viscosity of blood or plasma | VISE | 1163, 1164 |
| DIVISION 2 CHEMICAL PATHOLOGY | |  |
| Alanine Aminotransferase | ALT | 1558, 1559 |
| Albumin | ALB | 1558, 1559 |
| Alcohol (Ethanol) | ETOH | 1791, 1792 |
| Alkaline Phosphatase | ALP | 1558, 1559 |
| Alkaline Phosphatase Isoenzymes | ALPI | 1734, 1735 |
| Amniotic Fluid Examination | AFE | 1726, 1727 |
| Ammonia | NH3 | 1791, 1792 |
| Amylase | AMS | 1558, 1559 |
| Angiotensin coverting enzyme | ACE | 1791, 1792 |
| Aspartate Aminotransferase | AST | 1558, 1559 |
| Bicarbonate | HC03 | 1558, 1559 |
| Bilirubin (all fractions) | BILI | 1558, 1559 |
| Bilirubin (Neonatal) | BILN | 1791, 1792 |
| Blood Gases | GAS | 1590, 1591 |
| Calcium (total, dialysed or ionized) | CA | 1558, 1559 |
| Calculus Analysis | CALC | 1595, 1596 |
| Catecholamines | CAT | 1959, 1960 |
| Cholinesterase | CHSE | 1791, 1792 |
| Chloride | CL | 1558, 1559 |
| Cholesterol | CHOL | 1558, 1559 |
| Cystine (cysteine) | CYST | 1791, 1792 |
| C-reactive protein | CRP | 1558, 1559 |

**SCHEDULE—**continued

|  |  |  |
| --- | --- | --- |
| Approved Item Name of test in Schedule | Abbreviation | Numbers |
| Creatine Kinase | CK | 1558, 1559 |
| Creatine Kinase Isoenzymes | CKI | 1558, 1559 |
| Creatine Kinase Isoenzymes—quantitative or qualitative estimation by Electrophoresis | CKIE | 1734, 1735 |
| Creatinine | C | 1558, 1559 |
| Cryoglobulins | CGLB | 1575, 1576 |
| Cryofibrinogen | CFIB | 1575, 1576 |
| Dexamethazone Suppression test | DEXA | 2021, 2024 |
| Drug or Chemical Assays—Overdose | DRGO | 1598, 1599 |
| Drug Assays—Drug abuse treatment programme including urinary drug screen | DRGA | 1627, 1628 |
| Drug Assays—Therapeutic: |  |  |
| Antibiotics or antimicrobial chemotherapeutic agents (see under microbiology) | | |
| Acetylated Sulphadimidine | ASUL | 1712, 1713 |
| Amiodarone | AMIO | 1712, 1713 |
| Amitriptyline | AMIT | 1712, 1713 |
| Amylobarb | AMYL | 1712, 1713 |
| Barbitone | BARB | 1712, 1713 |
| Bromide | BRMD | 1712, 1713 |
| Butobarb | BUTO | 1712, 1713 |
| Carbamazepine (Tegretol) | CARB | 1712, 1713 |
| Chloral Hydrate | CHHY | 1712, 1713 |
| Chlorazepate | CHZP | 1712, 1713 |
| Chlorpromazine | CHLO | 1712, 1713 |
| Chloroquine | CLOQ | 1712, 1713 |
| Cimetidine | CMTD | 1712, 1713 |
| Clobazam | CLOB | 1712, 1713 |
| Clonazepam (rivotril) | CLON | 1712, 1713 |
| Cyclosporin A | CLSA | 1712, 1713 |
| Desethyl Amiodarone | DEAM | 1712, 1713 |
| Desipramine | DESI | 1712, 1713 |
| Diazepam | DIAZ | 1712, 1713 |
| Digoxin | DIG | 1712, 1713 |
| Diphenylhydantion (Dilantin) | DIL | 1712, 1713 |
| Disopyramide (Rythmodan) | DISO | 1712, 1713 |
| Dothiepin | DOTH | 1712, 1713 |
| Doxepin | DOXE | 1712, 1713 |
| Ethosuximide (Zarontin) | ETHO | 1712, 1713 |
| Flecainide | FLEC | 1712, 1713 |
| Hydroxychloriquine | HOCQ | 1712, 1713 |
| Imipramine | IMIP | 1712, 1713 |
| Lignocaine | LIGN | 1712, 1713 |
| Lithium | LI | 1712, 1713 |
| Methadone | MTDN | 1712, 1713 |
| Methotrexate | MTTA | 1712, 1713 |
| Methsuximide | MSUX | 1712, 1713 |
| Metronidazole | MRDZ | 1712, 1713 |
| Mexilitine (Mexitil) | MEX | 1712, 1713 |
| N Acetyl Procainamide | NAPC | 1712, 1713 |
| N Desalkyl Clobazam | NDAC | 1712, 1713 |
| N Desalkyl Doxepin | NDAD | 1712, 1713 |
| Nitrazepam | NITR | 1712, 1713 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Approved Item Name of test in Schedule | Abbreviation | Numbers |
| Nordothiepin | NDIP | 1712, 1713 |
| Nortriptyline | NORT | 1712, 1713 |
| Oxazepam | OXAZ | 1712, 1713 |
| Paracetamol | PARA | 1712, 1713 |
| Paraquat | PARQ | 1712, 1713 |
| Pentabarb | PENT | 1712, 1713 |
| Phenobarbitone | PHBA | 1712, 1713 |
| Phensoximide | PHEN | 1712, 1713 |
| Primidone | PRIM | 1712, 1713 |
| Procainamide | PCAM | 1712, 1713 |
| Prominal | PROM | 1712, 1713 |
| Propranolol | PPNO | 1712, 1713 |
| Quinalbarb | QUIB | 1712, 1713 |
| Quinine | QNN | 1712, 1713 |
| Quinidine | QUIN | 1712, 1713 |
| Salicylate-Asprin | SALI | 1712, 1713 |
| Sotalol | SALL | 1712, 1713 |
| Stellazine | STEL | 1712, 1713 |
| Sulphadimidine | SPDD | 1712, 1713 |
| Sulthiame (Ospolot) | SUL | 1712, 1713 |
| Theophylline | THEO | 1712, 1713 |
| Thiopentone | TOPO | 1712, 1713 |
| Thioridazine | THIO | 1712, 1713 |
| Tocainide | TOCN | 1712, 1713 |
| Trimipramine | TRIM | 1712, 1713 |
| Valproate (Epilum) | VALP | 1712, 1713 |
| Warfarin | WFR | 1712, 1713 |
| Therapeutic drugs which are not listed above must be written in full |  |  |
| Electrophoresis | EPP | 1734, 1735 |
| Elements: |  |  |
| Aluminium | AL | 1871, 1872 |
| Arsenic | AS | 1871, 1872 |
| Beryllium | BE | 1871, 1872 |
| Cadmium | CD | 1871, 1872 |
| Chromium | CR | 1871, 1872 |
| Copper | CU | 1871, 1872 |
| Gold | AU | 1871, 1872 |
| Lead | PB | 1871, 1872 |
| Manganese | MN | 1871, 1872 |
| Mercury | HG | 1871, 1872 |
| Nickel | NI | 1871, 1872 |
| Selenium | SE | 1871, 1872 |
| Strontium | SR | 1871, 1872 |
| Zinc | ZN | 1791, 1792 |
| Enzyme assays of solid tissue or tissues | ENZS | 1969, 1970 |
| Faecal Fat | FFAT | 1963, 1964 |
| Faecal Haemoglobin (chemical test) | FBT | 1577, 1578 |
| Faecal Porphyrins (qualitative test) | FPR | 1577, 1578 |
| Faecal Reducing Substances | FRS | 1577, 1578 |
| Faecal Haemoglobin (immunological test) | FBI | 1581, 1582 |
| Fructosamine | FRUC | 1558, 1559 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Approved Item Name of test in Schedule | Abbreviation | Numbers |
| Gamma Glutamyl Transpeptidase | GGT | 1558, 1559 |
| Globulin | GLOB | 1558, 1559 |
| Glucose | GLUC | 1558, 1559 |
| Glucose Tolerance Test | GTT | 1558, 1559 |
| Glycosylated Haemoglobin (Hb Ale) | GHB | 2043, 2044 |
| HDL Cholestrol | HDLC | 2039, 2040 |
| Hormones: |  |  |
| Adrenocorticotrophic hormone | ACTH | 2021, 2024 |
| Aldosterone | ALDS | 2021, 2024 |
| Androstenedione | ANDR | 2021, 2024 |
| C-Peptide | CPEP | 2021, 2024 |
| Calcitonin | CALT | 2021, 2024 |
| Cortisol | CORT | 2021, 2024 |
| Cyclic AMP | CAMP | 2021, 2024 |
| Dehydroepiandrosterone sulphate | DHEA | 2021, 2024 |
| Follicular Stimulating Hormone | FSH | 2021, 2024 |
| Gastrin | GAST | 2021, 2024 |
| Growth Hormone | GH | 2021, 2024 |
| Hydroxyprogesterone | OHP | 2021, 2024 |
| Insulin | INS | 2021, 2024 |
| Luteinizing Hormone | LH | 2021, 2024 |
| Oestradiol | E2 | 2021, 2024 |
| Oestriol | E3 | 2021, 2024 |
| Oestrone | El | 2021, 2024 |
| Parathyroid Hormone | PTH | 2021, 2024 |
| Prolactin | PROL | 2021, 2024 |
| Progesterone | PROG | 2021, 2024 |
| Renin | REN | 2021, 2024 |
| Sex Hormone Binding globulin | SHBG | 2021, 2024 |
| Testosterone | TES | 2021, 2024 |
| Urine Steroid Fraction or Fractions | USF | 2021, 2024 |
| Vasoactive Intestinal Peptide | VIP | 2021, 2024 |
| Hormone Receptor Assay | HRA | 2037-2038 |
| HIAA (Hydroxyindoleacetic acid) | HIAA | 1791, 1792 |
| HMMA (Hydroxy Methoxy Mandelic acid previously known as VMA) | HMMA | 1959, 1960 |
| HVA (Homovanillic acid) | HVA | 1959, 1960 |
| Hydroxproline | HYDP | 1791, 1792 |
| Intestinal disaccharidases | INTD | 1969, 1970 |
| Iron Studies (Iron, Transferrin and Ferritin) | IS | 1752, 1753 |
| Lactate | LACT | 1791, 1792 |
| Lactate Dehydrogenase | LDH | 1558, 1559 |
| Lactate Dehydrogenase Isoenzymes | LDI | 1734, 1735 |
| Lecithin/Sphingomyelin Ratio (Amniotic fluid) | LS | 1726, 1727 |
| Lipase | LIP | 1558, 1559 |
| Magnesium | MG | 1558, 1559 |
| MHPG (Methoxy Hydroxy Phenyethylene Glycol) | MHPG | 1959, 1960 |
| Osmolality, Serum or Urine | OSML | 1583, 1584 |
| Oxalate | OXAL | 1791, 1792 |
| PAA (Phenyl Acetic Acid) | PAA | 1959, 1960 |
| Palmitic acid in amniotic fluid | PALM | 1726, 1727 |
| pH measurement of body fluids other than urine | PH | 1575, 1576 |

**SCHEDULE—**continued

|  |  |  |
| --- | --- | --- |
| Approved Item Name of test in Schedule | Abbreviation | Numbers |
| Phosphate | PHOS | 1558, 1559 |
| Porphyrins (quantitative test, one or more fractions) | PR | 1959, 1960 |
| Potassium | K | 1558, 1559 |
| Prostatic Acid Phosphatase (one or more fractions) | ACP | 1738, 1739 |
| Protein (Total) | PROT | 1558, 1559 |
| Protein—Quantitative Estim. of Specific Protein: |  |  |
| Alpha feto protein | AFP | 1738, 1739 |
| Alpha-1 antitrypsin | AAT | 1738, 1739 |
| Alpha-2 microglobulin | AMIC | 1738, 1739 |
| Beta-2 microglobulin | BMIC | 1738, 1739 |
| CA-12S antigen | C125 | 1738, 1739 |
| CA-19.9 antigen | CA19 | 1738, 1739 |
| CA-15.3 antigen | CA15 | 1738, 1739 |
| C-l esterase inhibitor | CEI | 1738, 1739 |
| Caeruloplasmin | CPLS | 1738, 1739 |
| Carcinoembryonic antigen | CEA | 1738, 1739 |
| Ferritin | FERR | 1738, 1739 |
| Haptoglobins | HGLB | 1738, 1739 |
| Microalbumin | MALB | 1738, 1739 |
| Prostate specific antigen | PSA | 1738, 1739 |
| Transferrin | TRAN | 1738, 1739 |
| Pyruvate | PVTE | 1791, 1792 |
| Red Cell Folate and Serum B12 and if required, serum folate | RCF | 1770, 1771 |
| Serum B12 | B12 | 1768, 1769 |
| Serum Folate | FOL | 1768, 1769 |
| Sodium | NA | 1558, 1559 |
| Synacthen Stimulation Test | SYNS | 2021, 2024 |
| Thyroid Function Tests | TFT | 1983, 1984 |
| Thyrotrophin Releasing Hormone Test | TRH | 1985, 1986 |
| Triglycerides | TRIG | 1558, 1559 |
| Urate | URAT | 1558, 1559 |
| Urea | U | 1558, 1559 |
| Urine Bilirubin | UBIL | 1575, 1576 |
| Urine Cystine (Cysteine) | UCYS | 1575, 1576 |
| Urine Haemoglobin | UHB | 1575, 1576 |
| Urine Melanin (Melanogen) | UML | 1575, 1576 |
| Urine Myoglobin | UMY | 1575, 1576 |
| Urine Porphobilinogen | UPG | 1575, 1576 |
| Urine Porphyrins (qualitative test) | UPR | 1575, 1576 |
| Urine Urobilinogen | UUB | 1575, 1576 |
| Vitamin Quantitative Estimation of Vitamins A, Bl, B2, B3, B6, C or E | VIT | 1780, 1783 |
| Vitamin D | VITD | 1786, 1787 |
| Xylose | XYL | 1791, 1792 |
| DIVISION 3—MICROBIOLOGY | |  |
| Antibiotic and antimicrobial chemotherapeutic agents, quantitative assay | QAA | 2235, 2236 |
| Blood Culture | BC | 2123, 2124 |
| Cultural Examination of Faeces | FCS | 2117, 2118 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Approved Item Name of test in Schedule | Abbreviation | Numbers |
| Herpes Simplex Virus Investigation by Cultural Methods | HSVC | 2139, 2140 |
| Chlamydia Investigation by Cultural Methods Microbial Antibody Testing: | CHLC | 2139, 2140 |
| IgG, IgM, IgA, or total antibodies may be tested against various organisms. These are indicated by placing the letter G, M A and T respectively on the end of the 3 letter abbreviation |  | 2181, 2182 |
| Actinomycetes | ACT |
| Adenovirus | ADE | 2181, 2182 |
| Aspergillus | ASP | 2181, 2182 |
| Avian Precipitins (Bird Fancier’s Disease) | APP | 2181, 2182 |
| Blastomyces | BLM | 2181, 2182 |
| Bordetella pertussis | BOR | 2181, 2182 |
| Borrelia Berghoffer | BOB | 2181, 2182 |
| Brucella | BRU | 2181, 2182 |
| Campylobacter Jejuni | CAM | 2181, 2182 |
| Candida | CAN | 2181, 2182 |
| Chlamydia | CHL | 2181, 2182 |
| Coccidioides | CCC | 2181, 2182 |
| Coxsackie B1-6 | COX | 2181, 2182 |
| Cryptococcus | CRY | 2181, 2182 |
| Cytomegalovirus | CMV | 2181, 2182 |
| Cytomegalovirus serology in pregnancy | CMVP | 2145, 2146 |
| Dengue | DEN | 2181, 2182 |
| Diphtheria | DIP | 2181, 2182 |
| Echinococcus | ECC | 2181, 2182 |
| Echo-coxsackie group | ECH | 2181, 2182 |
| Entamoeba Histolytica | AMO | 2181, 2182 |
| Epstein Barr Virus | EBV | 2181, 2182 |
| Fluorescent Treponemal antibody-absorption test (FTA-ABS) | FTA | 2181, 2182 2181, 2182 |
| Haemophilus | HUS |
| Hepatitis delta antibody—Anti-delta | HDA | 2181, 2182 |
| Histoplasma | HIP | 2181, 2182 |
| Hydatid | HYD | 2181, 2182 |
| Influenza A | FLA | 2181, 2182 |
| Influenza B | FLB | 2181, 2182 |
| Legionella pneumophila—Serogroup 1 | LP1 | 2181, 2182 |
| Legionella pneumophila—Serogroup 2 | LP2 | 2181, 2182 |
| Leishmaniasis | LEI | 2181, 2182 |
| Leptospira | LEP | 2181, 2182 |
| Listeria | LIS | 2181, 2182 |
| Measles | MEA | 2181, 2182 |
| Micropolyspora faeni | MIC | 2181, 2182 |
| Mumps | MUM | 2181, 2182 |
| Murray Valley Encephalitis | MVE | 2181, 2182 |
| Mycoplasma pneumoniae | MYC | 2181, 2182 |
| Neisseria gonorrhoea | GON | 2181, 2182 |
| Newcastle Disease | NCD | 2181, 2182 |
| Parainfluenza 1 | PF1 | 2181, 2182 |
| Parainfluenza 2 | PF2 | 2181, 2182 |
| Parainfluenza 3 | PF3 | 2181, 2182 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Approved Item Name of test in Schedule | Abbreviation | Numbers |
| Paratyphi | PTY | 2181, 2182 |
| Pertussis | PER | 2181, 2182 |
| Pneumococcus | PCC | 2181, 2182 |
| Poliomyelitis | PLO | 2181, 2182 |
| Proteus OX 19 | POX | 2181, 2182 |
| Proteus OXK | POK | 2181, 2182 |
| Q fever | QFF | 2181, 2182 |
| Rapid Plasma Reagin test | RPR | 2181, 2182 |
| Respiratory Syncytial Virus | RSV | 2181, 2182 |
| Ross River Virus | RRV | 2181, 2182 |
| Rubella | RUB | 2145, 2146 |
| Rubella Serology in Pregnancy | RUBP | 2181, 2182 |
| Salmonella typhi (H) | SAH | 2181, 2182 |
| Salmonella typhi (O) | SAO | 2181, 2182 |
| Schistosoma | STO | 2181, 2182 |
| Streptococcal Serology—Anti-D-NASE B titre | ADNB | 2181, 2182 |
| Streptococcal Serology—Anti-Streptolysin O | ASOT | 2181, 2182 |
| Tetanus | TET | 2181, 2182 |
| Thermoactinomyces vulgaris | THE | 2181, 2182 |
| Thermopolyspora | TPS | 2181, 2181 |
| Toxocara | TOC | 2181, 2182 |
| Toxoplasma | TOX | 2181, 2182 |
| Toxoplasma serology in pregnancy | TOXP | 2145, 2146 |
| Treponema pallidum haemagglutin test | TPHA | 2181, 2182 |
| Trichonosis | TOS | 2181, 2182 |
| Typhus, Weil-Felix | TYP | 2181, 2182 |
| Varicella zoster | VCZ | 2181, 2182 |
| Venereal Disease Research Laboratory (VDRL) | VDRL | 2181, 2182 |
| Yersinia enterocolytica | YER | 2181, 2182 |
| Microbial antibody tests which are not listed above must be written in full |  |  |
| Hepatitis Serology |  | 2229, 2230 |
| Hepatitis Serology in acute hepatitis | HEP |  |
| Hepatitis B Serology in follow-up of proven Hepatitis B  Hepatitis B surface Antigen HBsAg | HEPB | 2231, 2232 |
| HBSA | 2221, 2222 |
| Hepatitis B Serology to define immune status | HEPI | 2223, 2224 |
| Microbial Antigen Testing: |  |  |
| Chlamydia | CHLY | 2133, 2134 |
| Herpes Simplex Virus | HSV | 2133, 2134 |
| CSF antigens—Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus | CSFA | 2129, 2130 |
| Cryptococcal antigen | CRYN | 2129, 2130 |
| RSV—respiratory Syncytial virus | RSVN | 2129, 2130 |
| Varicella zoster | VCZN | 2129, 2130 |
| Microscopic examination of material other than blood | M | 2083, 2084 |
| Microscopic examination of faeces for parasites | OCP | 2085, 2086 |
| Microscopy and culture of material from Nose, Throat, Eye or Ear | MCS1 | 2087, 2088 |
| Microscopy and culture of material from Skin, Superficial sites, urethra, vagina, cervix, sputum or Rectum | MCS2 | 2089, 2090 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Approved Item Name of test in Schedule | Abbreviation | Numbers |
| Microscopy and culture of material from post Operative Wounds, Aspirations of Body Cavities, Synovial fluid, CSF and operative or biopsy specimens | MCS3 | 2098, 2099 |
| Microscopy and culture of Sputum for Mycobacteria | AFB | 2119, 2020 |
| Urine microscopy, culture, identification and sensitivity | UMCS | 2127, 2128 |
| DIVISION 4—IMMUNOLOGY | |  |
| Specific IgG or IgE antibodies | ALLG | 2259, 2260 |
| Antibodies to Tissue Antigens: |  |  |
| Acetylcholine Receptor | ARA | 2271, 2274 |
| Adrenal cell | ADR | 2271, 2274 |
| Cardiolipin | ACL | 2271, 2274 |
| Centromere | ACA | 2271, 2274 |
| Gliad in IgA | GLIA | 2271, 2274 |
| Gastric parietal cell | PCA | 2271, 2274 |
| Glomerular basement membrane | GBA | 2271, 2274 |
| Insulin Receptor Antibodies | INSA | 2271, 2274 |
| Intercellular cement substance of skin | ICCS | 2271, 2274 |
| Jo-1 | JOl | 2271, 2274 |
| Keratin | KERA | 2271, 2274 |
| Liver/Kidney microsomes | LKA | 2271, 2274 |
| Mitochondria | MA | 2271, 2274 |
| Parathyroid | PTHA | 2271, 2274 |
| PM-1 | PM1 | 2271, 2274 |
| Reticulin | RCA | 2271, 2274 |
| Rheumatoid Factor (all tests including Latex test) | RF | 2281, 2282 |
| SCL 70 | SCL | 2271, 2274 |
| Skeletal Muscle | SLA | 2271, 2274 |
| Skin basement membrane | SKA | 2271, 2274 |
| Smooth Muscle | SMA | 2271, 2274 |
| Thyroglobulin | TGA | 2271, 2274 |
| Thyroid Microsomal | TMA | 2271, 2274 |
| TSH Receptor Antibody test | TSHA | 2271, 2274 |
| Tissue antigens which are not listed above must be written in full |  |  |
| Antibodies to Nuclear Antigens—detection | ANA | 2261, 2262 |
| Antibodies to Nuclear Antigens—quantitation and measurement of DNA binding if positive ANA | ANAP | 2263, 2266 |
| Antibodies to Extractable Nuclear Antigens—detection | ENA | 2267, 2268 |
| Antibodies to Extractable Nuclear Antigens—characterization of antibodies if positive ENA | ENAP | 2269, 2270 |
| Complement total, C3 or C4 | COM | 2289, 2290 |
| Other complements must be specified |  |  |
| HLA Typing, comprising A, B, C and DR phenotypes | HLA | 2321, 2322 |
| HLA Typing, one or more antigens | HLAN | 2323, 2324 |
| Immunoglobulins G, A, M or D | IG | 2245, 2246 |
| Immunoglobulin G, sub classes 1-4 | SIGG | 2255, 2256 |
| Immunoglobulins E | IGE | 2261, 2262 |
| Leucocyte Fractionation | LF | 2313, 2314 |
| Leucocyte functional Tests | LFF | 2315, 2316 |
| Leucocyte Surface Markers to assess Lymphoid populations | LSML | 2317, 2318 |

**SCHEDULE**—continued

|  |  |  |
| --- | --- | --- |
| Approved Item Name of test in Schedule | Abbreviation | Numbers |
| Leucocyte Surface Markers in investigation of probable haematological malignancy | LSMH | 2319, 2320 |
| Mantoux Test | MANT | 2325, 2326 |
| Paraprotein Investigation by Immuno-electrophoresis or immunofixation | PPRO | 2239, 2240 |
| Paraprotein Investigation on concurrently collected serum and urine | PPSU | 2241, 2242 |
| DIVISION 5 HISTOPATHOLOGY | |  |
| Electron microscopy and biopsy material | EM | 2333, 2337 |
| Histopathology of biopsy material | HIST | 2327, 2328 |
| Immediate frozen section diagnosis of biopsy material | FS | 2329, 2330 |
| Immunohistochemical investigation of biopsy material | IHIS | 2331, 2332 |
| DIVISION 6 CYTOPATHOLOGY | |  |
| Cytology from cervix or vagina | CXCY | 2338, 2339 |
| Cytology from skin, nipple discharge, lip, mouth, nose or anus | SMCY | 2340, 2341 |
| Cytology from body fluids, urine or washing | BFCY | 2340, 2341 |
| Cytology from body fluids, aspiration of solid tissues | FNCY | 2350, 2351 |
| Cytology from fine needle aspiration of solid tissues— aspiration or attendance by pathologist | FNCP | 2355, 2356 |
| DIVISION 7 CYTOGENETICS | |  |
| Chromosome studies | CS | 2360, 2361 |
| Chromosome studies of blood | CSB | 2363, 2364 |
| Chromosome identification by banding techniques | CSI | 2365, 2366 |
| DIVISION 8 INFERTILITY AND PREGNANCY TESTS | |  |
| Semen examination for spermatozoa | SES | 2370, 2371 |
| Huhner’s test | HT | 2370, 2371 |
| Semen examination | SEE | 2372, 2373 |
| Sperm antibodies | SAB | 2377, 2378 |
| Sperm penetrating ability | SPA | 2377, 2378 |
| Chorionic gonadotrophin for pregnancy diagnosis | HCG | 2379, 2380 |
| Chorionic gonadotrophin for diagnosis of specified conditions | HCGD | 2384, 2385 |

**NOTES**

1. No. 41, 1987, as amended. For previous amendments, see No. 79, 1988.

2. No. 42, 1974, as amended. For previous amendments, see No. 58, 1975; Nos. 59, 91, 101, 109 and 157, 1976; No. 75, 1977; Nos. 36, 89 and 133, 1978; Nos. 53 and 123, 1979; No. 132, 1980; Nos. 118 and 176, 1981; Nos. 49, 80 and 112, 1982; Nos. 54 and 139, 1983; Nos. 15, 46, 63, 120, 135 and 165, 1984; Nos. 24, 65, 70, 95 and 167, 1985; Nos. 28, 75 and 94, 1986; Nos. 44, 131, 132 and 141, 1987; and Nos. 85, 87, 99 and 155, 1988.

**NOTES**—continued

3. No. 95, 1953, as amended. For previous amendments, see No. 68, 1955; Nos. 55 and 95, 1956; No. 92, 1957; No. 68, 1958; No. 72, 1959; No. 16, 1961; No. 82, 1962; No. 77, 1963; No. 37, 1964; Nos. 100 and 146, 1965; No. 44, 1966; Nos. 14 and 100, 1967; No. 100, 1968; No. 102, 1969; No. 41, 1970; No. 85, 1971; No. 114, 1972; Nos. 49 and 202, 1973; No. 37, 1974; Nos. 1, 13 and 93, 1975; Nos. 1, 60, 91, 99, 108, 157 and 177, 1976; Nos. 98 and 100, 1977; Nos. 36, 88, 132 and 189, 1978; Nos. 54, 91 and 122, 1979; Nos. 117 and 131, 1980; Nos. 40, 74, 92, 118, 163 and 176, 1981; Nos. 49, 80 and 112, 1982; Nos. 35, 54 and 139, 1983; Nos. 46, 63, 72, 120, 135 and 165, 1984; Nos. 24, 53, 65, 70, 95, 127 and 167, 1985; Nos. 28, 75, 94 and 115, 1986; Nos. 22, 44, 72, 118, 131 and 132, 1987; and Nos. 79, 87, 99 and 155, 1988.

4. No. 147, 1974, as amended. For previous amendments, see No. 91, 1976; No. 100, 1977; No. 118, 1980; No. 118, 1981; Nos. 26 and 80, 1982; No. 139, 1983; No. 63, 1984; Nos. 24, 52 and 65, 1985; No. 115, 1986; and No. 72, 1987.

5. No. 215, 1973, as amended. For previous amendments, see No. 80, 1974; No. 96, 1975; Nos. 60 and 178, 1978; Nos. 26, 108, 136 and 155, 1979; No. 160, 1980; Nos. 61, 74 and 176, 1981; Nos. 78 and 111, 1982; Nos. 39 and 128, 1983; Nos. 63, 73 and 164, 1984; Nos. 65 and 187, 1985; and Nos. 87, 109 and 123, 1988.

6. No. 164, 1985, as amended. For previous amendments, see No. 75, 1986; No. 132, 1987; and Nos. 79 and 80, 1988.

[*Minister’s second reading speech made in —*

*House of Representatives on 10 May 1989*

*Senate on 26 May 1989*]